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Abstract 
Purpose: This study assessed the benefits to the heart and lung of using scanned electron beams 
and continuous energy spacing (ΔR90=0.1 cm) for left-side post-mastectomy radiotherapy 
(PMRT) patients previously treated with volumetric modulated arc therapy (VMAT). Such 
beams offer a sharper distal falloff (R90-10) than do currently available scattered, discrete energy 
beams, which increases sparing of healthy organs distal to the target. 
Methods: Seven left-side PMRT patients previously treated with VMAT at the Mary Bird 
Perkins Cancer Center were planned in this study. The patients were divided into two sets; 
Patient Sets 1 (three patients) and 2 (four patients) used one and two fields, respectively, to plan 
chest wall irradiation. Four and five intensity modulated bolus electron conformal therapy (IM-
BECT) plans, respectively, were created per patient using combinations of scattered/scanned and 
discrete/continuous energy beam data. For Patient Set 2 the inferior edge of the upper field was 
feathered to match the penumbra of the superior edge of the lower field. Dose distributions and 
dose volume histograms (DVHs) were used to evaluate plan quality, to calculate physical dose 
metrics for the target, heart, and lung, and to calculate the biological metrics, normal tissue 
complication probability (NTCP), and secondary cancer complication probability (SCCP) for the 
heart and lung. 
Results: Scanned and/or continuous energy electron beams showed patient-dependent, 
sometimes significant reductions in both physical and biological dose metrics for the heart and 
lung. For patient CW1, as compared to scattered, discrete energy beams, scanned, continuous 
energy beams reduced V22.5Gy from 10.4% to 2.3%, V30Gy from 3.1% to 0.1%, Dmean from 8.3 Gy 
to 4.3 Gy, and NTCP from 0.4% to 0.1% for the heart. The comparison reduced V20Gy from 
17.2% to 10.7% and SCCPlin from 14.4% to 8.7% for the lungs. Such reductions tended to 
x 
 
increase as R90 increased. Compared to VMAT, IM-BECT plans with scanned beams on average 
reduced V22.5Gy from 9.4% to 3.4%, Dmean from 9.3 Gy to 4.4 Gy, and NTCP from 1.0% to 0.2% 
for heart and Dmean from 8.8 Gy to 7.1 Gy, NTCP from 2.8% to 0.2%, and SCCPlin from 15.1% 
to 10.2% for lung. 
Conclusion: Scanned and/or continuous energy electron beam treatment plans showed reduced 
physical and biological dose metrics for heart and lung compared to scattered, discrete energy 
beams. These improvements were patient dependent, although patients requiring higher energy 
beam(s) tended to show the greatest benefits. 
 
1 
Chapter 1. Introduction 
1.1. Background and Significance 
1.1.1. Breast Cancer and Post- Mastectomy Chest Wall Irradiation 
In 2019, breast cancer comprised 30% of all new cancer diagnoses in women, the highest 
incidence rate of all cancers in women.1 While the overall cancer incidence rate for women has 
stayed relatively constant over the past few decades, breast cancer incidence rates have been on 
the rise. From 2006 to 2015 in the United States, breast cancer incidence increased by 0.3%-0.4% 
per year in non-Hispanic white and Hispanic women, by 0.7%-0.8% per year in black and 
American Indian/ Alaska Native women, and by 1.8% per year in Asian/ Pacific Islander women.2 
Contributing factors may be the obesity epidemic and declining parity.3, 4 
15% of all deaths due to cancer, corresponding to 41,760 total patients, were attributed to 
breast cancer in the United States, which has the second highest mortality rate of all cancers in 
women. However, the 5-year survival rate for all stages of breast cancer is 90%, which is the third 
highest of all cancers.1 This suggests that the high mortality rate is primarily due to its high 
incidence rate. 
Surgery, radiation, or a combination of the two are common treatment options for breast 
cancer. A mastectomy, complete removal of the breast tissue, is often combined with radiotherapy 
to eradicate microscopic disease in the remaining chest wall, referred to as post-mastectomy 
radiotherapy (PMRT). 
When planning post-mastectomy radiation treatments, the chest wall is defined by the 
following anatomical boundaries based on consensus definitions from RTOG breast cancer Atlas: 
to the caudal border of the clavicle head on the cranial side, to the skin on the anterior side, to the 
rib-pleural interface (including the pectoralis muscles, chest wall muscles, and ribs) on the 
posterior side, to the mid axillary line (excluding latissimus dorsi) on the lateral side, to the sternal-
2 
rib junction on the medial side, to the clinical reference on the caudal side.5 The supraclavicular 
region, which is treated with photon radiotherapy, has the following anatomical boundaries based 
on the RTOG breast cancer Atlas: the upper border is below the level of the cricoid, the medial 
border is at the vertebral pedicles and lateral border consists of the portion of the axilla that 
remained undissected, and the inferior border extends to the caudal aspect of the clavicular head.5 
See Figure 1.1 for outlines of the regions and heart. 
  
Figure 1.1. RTOG breast cancer atlas image of chest wall: sagittal (upper left), coronal (upper 
right), and transverse (lower right) planes. Shown are the chest wall, heart, and internal mammary 
glands.6  
The standard radiation dose for post-mastectomy radiotherapy is 50 Gy to the target, 
delivered as 2 Gy daily fractions over 5 weeks. Monitor units are calculated to give the prescribed 
3 
dose to 95% of the target volume.7, 8 Due to the high survival rate, the long-term side effects of 
post-mastectomy radiotherapy must be examined. For any post-mastectomy radiotherapy 
treatment, the lung is a primary organ at risk. In addition, for cases involving left-side post-
mastectomy chest wall irradiation, the heart is also of concern, as the heart is distal to the left side 
of the chest wall. Cardiac late effects such as pericarditis, ischemic heart disease, congestive heart 
failure, and coronary atherosclerosis can occur if the dose delivered to the heart is too high.9 
However, if the heart receives under 30 Gy of dose, there is not an increased risk of cardiac 
mortality.10 Thus, the present study evaluates the risk of developing radiotherapy side effects to 
the heart with V30 Gy, the volume of the heart receiving at least 30 Gy of dose compared to the total 
heart volume. Radiation pneumonitis, or acute inflammation of the lung, and pulmonary fibrosis, 
or scarring and stiffening of scar tissue, can both occur if too large a volume of the lung is 
irradiated.11 Thus, the present study evaluates the risk of developing radiotherapy side effects to 
the lung with V20 Gy, the volume of the lungs receiving at least 20 Gy of dose compared to the total 
lung volume.12, 13 
Because of the improvement in overall survivorship for invasive breast cancer patients 
when using PMRT, many different advanced radiotherapy techniques have been developed. These 
techniques include fixed-beam intensity-modulated radiotherapy,14 non-coplanar volumetric 
modulated arc therapy (VMAT),15 multiple arc VMAT,16 mixed beam therapy (photons and 
electrons),17 electron arc therapy,18 and helical tomotherapy19. A previous study conducted by Xie 
et al.20 evaluated many of these different treatment modalities for treating PMRT patients by the 
following metrics: planning target volume (PTV) coverage, dose homogeneity index (DHI), 
conformity index (CI), dose to organs at risk (OARs), normal tissue complication probability 
(NTCP) of pneumonitis, lifetime attributable risk (LAR) of second cancers, and risk of coronary 
4 
events (RCE). They found that fixed-beam IMRT delivered the lowest mean dose to contralateral 
breast and exhibited lowest LAR of secondary contralateral breast cancer; non-coplanar-VMAT 
delivered the lowest mean dose to lungs, exhibited lowest LAR of secondary lung cancer and 
lowest NTCP of pneumonitis; mixed beam therapy delivered the lowest mean dose to heart and 
exhibited lowest RCE for the heart; and tomotherapy plans provided the most optimal target 
coverage while delivering higher dose to OARs than other techniques.  
Opp et al.21 performed a similar study to compare the following PMRT techniques: 
opposed tangents with wedges, opposed tangents with field in field modulation, 8-field IMRT, and 
bolus electron conformal therapy (BECT). They compared the dose homogeneity and normal 
tissue dose parameters for these four sets of plans while maintaining a constant PTV coverage. 
They found that IMRT and BECT provided the lowest V25 Gy doses for the heart, while field in 
field had the lowest average lung dose. In addition, IMRT provided the lowest V20 Gy doses for the 
lung and BECT provided the lowest mean heart dose. This study, along with Xie et al.’s study 
shows that using electron radiotherapy for PMRT has OAR sparing benefits while maintaining 
adequate PTV coverage.  
1.1.2. Electron Beam Radiation Therapy 
Therapeutic electron beams are characterized by a unique depth dose profile and finite 
range that can be useful for irradiating planning target volumes (PTVs) within 6 cm of the patient 
skin surface while sparing distal organs and tissues. Superficial cancers and shallow tumor sites, 
such as skin, spinal cord, head and neck, and chest wall are effectively treated with electron 
beams.22–24 This includes PMRT, for which there are many electron beam techniques, such as 
abutted beams of different energies,19 electron arc therapy,18 and BECT.21, 25, 26 
Clinically available electron beams typically have energies ranging from approximately 7 
MeV to 20 MeV, which have therapeutic ranges (R90) of approximately 2.0 cm to 6.0 cm, 
5 
respectively. Such electron beams deliver a fairly uniform dose from the surface to R90, with a 
sharp distal falloff (R90-10), which spares underlying healthy tissue and critical organs. This rapid 
dose falloff beyond the target volume depth decreases the normal tissue complication probability 
while preserving high tumor control. This is the primary advantage of electron beam therapy over 
conventional photon therapy. Figure 1.2 characterizes the depth dose profile of an electron beam. 
 
Figure 1.2. Characteristic depth dose curve of a megavoltage electron beam. The dose is 
normalized at R100, the depth of maximum dose. The maximum dose, Dm or 100%, does not occur 
at the surface, but deeper in the volume, due to multiple Coulomb scattering. Typically the dose 
ranges from the lesser of Ds or 90% to 100% in the planning target volume (PTV). 
27, 28 
Typically, electron beams are delivered in such a way that as much of the PTV is contained 
in the plateau (surface to R90 depth) with dose ranging from 100% to 90% (or Ds, if lower) without 
overdosing distal healthy tissue. In three dimensions, distal PTV depth varies with off-axis 
position, and ideally, the lowest energy that can contain the PTV within the 90% isosurface should 
be used. Often a higher than required energy is used in conjunction with a tissue-equivalent bolus 
to treat the PTV, due to the discretely spaced energies of clinically available electron beams, as 
illustrated in Figure 1.3 for the Elekta radiotherapy accelerator. In such a case, a tissue-equivalent 
bolus usually is placed superficial to the target, shifting the dose distribution towards the surface 
6 
and R90 toward the distal PTV surface. Note in Figure 1.3 that higher energy electron beams have 
a more gradual falloff (increased R90-10), delivering more dose to healthy tissues distal to the PTV. 
This effect is amplified in lung, compared to unit density tissue, due to its lower density 
(approximately 0.25-0.33 times that of unit density tissue).  
 
Figure 1.3 Percent depth dose curves for clinically available Elekta energies at Mary Bird Perkins 
Cancer Center (MBPCC). Note that higher energy beams that are more penetrative have a greater 
dose falloff region (R90-10). 
1.1.3. Scanned Electron Beams 
Historically, two methods have been used for broadening and flattening therapeutic electron 
beams: dual scattering foil and scanned beams. Dual scattered electron beams use a thin high-Z 
metal foil (placed 90-100 cm upstream of isocenter) to broaden the beam and a Gaussian-shaped 
metal foil, typically aluminum (placed 5-20 cm downstream of primary foil) to flatten the resulting 
forward peaked beam.29, 30 Scanned electron beams use two scanning dipole magnets to scan the 
electron beam in orthogonal directions to spread and flatten the beam. The scanning patterns can 
7 
be row by row, spiraled, or quasi random.31 Because scanned beams do not have the thick primary 
scattering foil, there is less bremsstrahlung production and energy straggling in the treatment head, 
reducing R90-10. 
Hence, scanned beams can offer superior dose distributions compared to scattered beams, 
which can have clinical advantages. This is illustrated in Figure 1.4, which compares a scattered 
and a scanned beam, each having an R90 of 5.0 cm. Note the difference in the dose falloff region: 
the scanned beam having a lower R90-10, reduced Rp (corresponding reduced beam energy, Ep,0), 
and reduced D. 
 
Figure 1.4. Percent depth dose curve for both a scanned (Therac 20) and scattered (Elekta) electron 
beam with R90 of 5.0 cm. The R90-10 of the scanned beam is 2.42 cm, versus 3.01 cm for the 
scattered beam, which corresponds to 0.59 cm of additional normal tissue sparing. 
These effects are illustrated in Figure 1.5, which compares plots of R90 vs Ep,0 and R90-10 vs 
Ep,0 for scattered and scanned beams. The increased benefit of scanned beams can be better 
8 
appreciated by combining the data of Figure 1.5 into a plot of R90-10 versus R90 for scattered and 
scanned beams, shown in Figure 1.6. For example, an R90 of 5.0 cm requires a 16.2 MeV scattered 
beam versus a 15.05 MeV scanned beam (demarcated in Figure 1.5), which results in a decreased 
R90-10 (3.0 cm versus 2.4 cm), decreased Rp (7.9 cm vs 7.4 cm), and decreased D. Thus, a lower 
energy scanned beam can be used to treat the same target as a scattered beam, while providing 
additional healthy tissue sparing. Unfortunately, due to specific cases of overdose due to scanning 
failures, scanning beam electron therapy machines were phased out in the 1990s, and currently  
scattered electron beams are almost exclusively used clinically.32
 
Figure 1.5. R90 and R90-10 as a function of energy for both scanned and scattered beams in water. 
The scanned electron beam has a greater R90 for each energy compared to the scattered beam and 
has a lower R90-10 for each energy compared to the scattered beam. Points demarcate discrete 
energies on selected Therac 20 and Elekta machines, and solid lines are guides for the eye. The 
dashed lines indicate Ep,0 of beams having R90 of 5.0 cm. 
1.1.4. Continuous Beam Energy 
Another impact on the distal dose falloff is the spacing between discrete electron beam 
energies for both scattered and scanned electron beam radiotherapy machines. This is illustrated 
in Figure 1.6, where electron beam energies are indicated by the points, showing that energies are 
spaced at approximately  0.5 to 1.0 cm R90 intervals in water, which corresponds to approximately 
9 
1.5 to 4.0 MeV intervals in Ep,0. The impact of this is illustrated in Figure 1.7, which compares 
scattered beam %DD curves of a beam with an R90 of 5.2 cm with one having an R90 value of 5.9 
cm with 0.7 cm of bolus. In such a case, the R90-10 is 3.4 cm vs. 4.3 cm, illustrating the downside 
of having to use a higher energy with bolus when continuous energies are not available.  
 
Figure 1.6. R90-10 as a function of R90 for both scanned and scattered beams in water. The scanned 
beam has a lower R90-10 for each R90 than the scattered beam, so that there is less dose falloff for 
treating the same depth. Points demarcate discrete energies on selected Therac 20 and Elekta 
machines. Solid lines are guides for the eye, and the dashed lines indicate scattered beams with 
R90=5.9 cm + 0.7 cm bolus and R90=5.2 cm and a scanned beam with R90=5.2 cm. 
In addition to continuous energy beams, if scanned beams were available, R90-10 would be 
further reduced to 2.5 cm. Hence, compared to the scattered, discrete energy beam, the scanned 
continuous energy beam reduces R90-10 by almost 2 cm (from 4.3 to 2.5 cm). This advantage is 
further illustrated by comparing the corresponding depth dose curves in Figure 1.7, which  first 
simulates the water-equivalent heart lying 0.5 cm distal to the 5.2 cm deep PTV, and second it 
simulates the 0.25 density lung lying 1.0 cm distal to the 5.2 cm deep PTV. 
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Figure 1.7. Comparison of percent depth doses curves for continuous versus discrete spacing for 
two scattered Elekta beams and for scanned, continuous energy Therac beam. Percent depth dose 
curves for the scattered electron beams have an Ep,0=17 MeV and Ep,0=20.5 MeV+0.7 cm bolus 
(both corresponding to R90=5.2 cm). Percent depth dose curves for the scanned beam have an 
Ep,0=15.6 MeV (corresponding to R90=5.2 cm).  Shown for heart lying distal to the PTV (top) and 
lung lying distal to PTV (bottom). The red dashed lines indicate the starting depth for which the 
DVHs in Figure 1.8 are generated. 
These effects of using scanned, continuous energy beams over scattered, continuous energy beams 
over currently available scattered, discrete energy beams are demonstrated in DVHs for a 
simulated patient geometry, as shown in Figure 1.8. These DVHs are generated from the percent 
depth dose curves shown in Figure 1.7.  
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Figure 1.8. Simulated DVHs for a generic patient, shown for the heart (left) and lung (right). All 
three beams shown are used to treat a target that is 5.2 cm thick. Using percent depth dose curves 
in Figure 1.7, the heart V30Gy is reduced from 28% to 18% to 12%, and the lung V20Gy is reduced 
from 24% to 14% to 8%, when using scattered, discrete energy beams (green line)scanned, 
continuous energy beams (blue line) versus scanned, continuous energy beams (blue line), 
respectively.  
While these discretely spaced electron energies can effectively treat patients, they can 
introduce greater dose to normal tissue than an ideal treatment. The ability to select the optimal 
beam energy from a set of continuously variable electron energies and/or use scanned beams versus 
scattered beams could provide the ability to improve patient treatments by delivering less dose to 
normal tissues than using currently available electron beams. To further investigate this concept, 
we believe it appropriate to utilize the most technically advanced method for electron planning 
and delivery currently available, intensity modulated bolus electron conformal therapy (IM-
BECT).33, 34 
1.1.5. Intensity Modulated-Bolus Electron Conformal Therapy (IM-BECT) 
Electron conformal therapy (ECT) is the use of one or more electron beams to contain the 
PTV to the 90% dose surface, achieve as homogenous dose distribution as possible or a prescribed 
heterogeneous dose distribution to the PTV, and deliver minimal dose to underlying critical 
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structures and normal tissues.35 Bolus ECT (BECT) has been shown clinically useful for posterior 
chest wall,25, 36 PMRT,21, 25, 26 head and neck,33, 37 and extremities.36 Currently, BECT planning 
and delivery technology is commercially available from .decimal LLC (Sanford, FL) and from 
Adaptiiv (Halifax, NS, Canada), which are based on the original work of Low et al.38 and a later, 
similar work by Su et al,36 respectively. These technologies use a bolus (tissue equivalent range 
compensator) that shapes the distal side of the dose distribution (e.g. 90% dose surface) to the 
PTV. The bolus can be milled machinable wax39 or 3D printed polyethylene terephthalate glycol-
modified (PETG) or polylactic acid (PLA).36, 40 The bolus is patient-specific, and its distal surface 
conforms to the patient surface. However, bolus electron conformal therapy (BECT) can produce 
increased dose heterogeneity in the PTV due to the irregular proximal surface of the bolus creating 
lateral side scatter disequilibrium. 
Kudchadker et al. showed that intensity modulation used in conjunction with BECT can 
significantly improve dose homogeneity in the PTV.33 In this case, the bolus provides a high level 
of dose conformation to the PTV, and the intensity modulation improves dose homogeneity, 
reducing hot and cold spots.  
Recently, a new technology for passive electron intensity modulation has been developed 
and studied.34, 41–43 For intensities 50% or greater of the incident beam, modulation is achieved 
using tungsten island blocks of varying diameters placed on a hexagonal grid and embedded in 
low density, machinable foam within the patient collimating aperture. The block diameters are 
selected to modulate electron fluence, analogous to metal compensators used in intensity 
modulated x-ray therapy.34 Intensity modulation is useful for delivering a highly conformal and 
homogenous (or prescribed heterogeneous) dose distribution. 
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A later study by Kudchadker et al. showed the improvement in dose distribution as well as 
the reduction of hot and cold spots when using IM-BECT over BECT for the post-mastectomy 
chest wall.33 These results are shown in Figure 1.9.  
1.2. Motivation for Research 
Opp et al. compared bolus electron conformal therapy with conventional techniques for the 
treatment of left-side chest-wall post-mastectomy patients.21 That study completed treatment plans 
for twenty-five patients comparing opposed tangents with wedges, opposed tangents with field-in-
field modulation, 8-field IMRT, and BECT. Results showed that IMRT and BECT provided the 
lowest heart V25 Gy doses, and BECT had the lowest mean heart dose. Field-in-field provided the 
lowest mean total lung dose and IMRT provided the lowest total lung V20 Gy. In some cases, BECT 
could not provide adequate coverage, and IMRT showed better dose homogeneity. When using 
IMRT, the contralateral breast and lung receive slightly higher doses compared to other techniques. 
Patient anatomy determines whether BECT is suitable, and patients with a maximal target depth 
of <5.7 cm could be treated with BECT. If the maximal depth of the target is >5.7 cm, IMRT 
provides better dose homogeneity and normal tissue sparing.21 
Previous work has shown that using IM-BECT over the heart and opposed IMXT elsewhere 
for PMRT has statistically significant advantages over using conventional techniques such as 
VMAT in some patients.43 Delivering IM-BECT treatments to the chest wall with scanned beams 
and continuously spaced energies should further reduce the dose to the heart and lung in PMRT.  
In the present study, only the chest wall portion of the PTV treated in PMRT, which can be 
treated with IM-BECT, will be studied, i.e. the supraclavicular PTV, normally requiring x-ray 
radiotherapy will be ignored. The chest wall treatment will be planned using one field, or if needed, 
two abutted fields, the lower “heart field” and upper “lung field.” The heart field will be treated 
with a lower energy, and the lung field will be treated with a higher energy. The objective of this 
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study is to verify and quantify the benefits of using scanned electron beams and/or continuously 
spaced electron beam energies for chest wall PMRT. 
 
Figure 1.9. Dose distributions comparing BECT and IM-BECT for post-mastectomy chest wall.33 
The PTV is marked with the dashed line in the transverse plane shown. (a) BECT resulting in a 
hot spot of 109.3% and (b) IM-BECT resulting in a reduced hot spot of 106.7%. 
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1.3. Hypothesis and Specific Aims 
1.3.1. Hypothesis 
For seven post-mastectomy radiotherapy left-side chest wall patients previously treated 
with volumetric modulated arc therapy (VMAT), treatment plans using intensity modulated bolus 
electron conformal therapy (IM-BECT) with a scanned electron beam and/or the capability of 
continuous energy spacing can be superior (increased sparing of heart and lung and reduced chance 
of secondary cancer) to plans made using IM-BECT with a passively scattered electron beam and 
discrete Elekta energy spacing. 
1.3.2. Specific Aims 
Aim 1, Generate Treatment Plans Assuming Different Electron Beam Technology: Generate IM-
BECT treatment plans for seven post-mastectomy radiotherapy (PMRT), left-side chest wall 
patients previously treated with volumetric modulated arc therapy (VMAT) using a range of 
applicable energies from 13 to 20 MeV. Treatment plans will be generated for combinations of 
scanned or passively scattered electron beams and discrete or continuous electron energy beams. 
Plans will be developed for the entire chest wall PTV, which had been contoured in accordance 
with RTOG breast cancer atlas guidelines while maintaining healthy tissue dose limits. Compute 
3D dose distributions and DVHs for each plan. 
Aim 2, Physical and Biological Dose Metrics for Plans: Compute physical dose metrics and 
resulting biological metrics for each of the plans for each of the seven patients. Physical dose 
metrics include (1) PTV: Dmax(maximum dose), Dmean (mean dose), D97% (Dose given to 97% of 
PTV volume) and V47.5 Gy (relative volume of PTV receiving 47.5 Gy, or 95% of the prescribed 
dose of 50 Gy), (2) Heart: Dmin, Dmax, Dmean, V22.5 Gy (relative volume of heart receiving 22.5 Gy), 
and V30 Gy (relative volume of heart receiving 30 Gy), and (3) Lung: Dmin, Dmax, Dmean, and V20 Gy 
(relative volume of lung receiving 20 Gy). Biological dose metrics include (1) Heart: NTCP 
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(normal tissue complication probability) and (2) Lung: NTCP, SCCPlin (secondary cancer 
complication probability, linear model), and SCCPlin-exp (secondary cancer complication 
probability, linear-exponential model). 
Aim 3, Analyze and Compare Plans using Metrics: Analyze the seven different sets of patient 
plans and determine the patient indications for using continuously spaced electron energies and 
scanned electron beams. Determine the differences in patient geometry and beam conditions that 
affect the utility of scanned versus scattered beams and continuous versus discrete energy 
spacing (Comparisons made in this aim are presented in the discussion section).  
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Chapter 2. Methods and Materials 
2.1. Aim 1—Generating Treatment Plans Assuming Different Electron Beam Technology 
The goal of Aim 1 is to develop IM-BECT plans for seven post-mastectomy radiotherapy 
left-side chest wall patients previously treated with volumetric modulated arc therapy (VMAT).17 
For each plan, this involves the following steps: 
1. Create initial electron plan. 
a. Beam Angle Selection 
b. PTV Segmentation 
c. Field Construction 
d. Energy Selection  
2. Improve beam penumbra matching using edge feathering. 
3. Design electron bolus for each field. 
4. Compute dose distributions for each field. 
5. Sum for the composite chest wall dose distribution. 
Steps 1 and 2 were completed using Pinnacle v9.10 (Philips Radiation Oncology Systems, 
Fitchburg, WI) treatment planning system and MATLAB code developed for this project. Steps 3 
and 4 were completed using a research version of p.d (.decimal LLC, Samford, FL). MIM (MIM 
Software Inc., Cleveland, OH) was used to assist in transferring files between platforms, 
completing step 5, and evaluating plan quality.  
For all plans, the prescription was 50 Gy to the 90% isodose line (100%, or 55.6 Gy, is the 
given dose for each field) in 25 fractions. However, to compare plans for the same patient, dose 
distributions were rescaled, so all plans delivered an identical dose to 50% of the PTV, based on 
the dose given to 50% of the PTV for Plan 1, defined later.  
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2.1.1. Patient Selection 
Seven left-side post-mastectomy chest wall patients were selected, each of whom fulfilled 
the following criteria: 
1. Received prior treatment with VMAT at the Mary Bird Perkins Cancer Center 
2. Part of a HIPAA compiled data set 
3. Subjects of previous retrospective treatment planning study by Heins8 (2016) and 
Doiron41 (2018). 
Each anonymized patient data set included previously defined contours (PTVs, normal 
structures, and skin surface) and CT images acquired on a 120 kVp large bore GE Lightspeed 16 
CT scanner (General Electric Medical Systems). Transverse CT planes were acquired every 0.25 
cm. The chest wall PTV and organs at risk, i.e. lung and heart, were previously contoured by the 
treating radiation oncologist. The patients and their corresponding data sets are referred to as CW1 
through CW9 (CW5 and CW9 were not included in this study due to software issues in our research 
version of p.d), matching the designations in Heins and Doiron.8, 41  
For planning purposes, the patient data was divided into two subsets, Patient Set 1 (CW1, 
CW3, CW6) and Patient Set 2 (CW2, CW4, CW7, CW8). Patient Set 1 was planned using a single 
field (single energy); Patient Set 2 was planned using two abutting fields (having different beam 
energies). 
2.1.2. Field Specifications for Patient Set 1 
For three patients (CW1, CW3, and CW6), further referred to as Patient Set 1, one electron 
field (energy) was sufficient to cover the entire PTV. In these cases, the deepest part of the PTV 
superficial to the heart is as deep or deeper than the portion of the PTV superior to the heart. Hence, 
only one PTV and one beam energy were necessary. The superior and inferior margins were set as 
2 cm, and the two lateral margins are set as 1.5 cm. Only four plans, Plan 1, Plan 3, Plan 4, and 
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Plan 5, were created for these patients (CW1, CW3, and CW6), corresponding to the plan 
designations described for Patient Set 2. A schematic of the fields and PTVs for each plan is shown 
in Figure 2.1. 
 
Figure 2.1. Schematic of PTVs and fields for Patient Set 1. For these patients, the superior border 
of the CW PTV (PTV Evaluate) is at the inferior border of the supraclavicular PTV (SC PTV).  
2.1.3. Field Specifications for Patient Set 2 
For four of the seven patients (CW2, CW4, CW7, and CW8), further referred to as Patient 
Set 2, the chest wall PTV was divided into two separate PTVs: the inferior (lower) PTV which is 
anterior to the heart and the inferior portion of the left lung, and the superior (upper) PTV which 
is anterior to lung, extending from the superior border of the inferior field to just inferior to the 
PTV for the supraclavicular nodes. The supraclavicular nodes were assumed to have been planned 
with x-rays which contribute insignificant dose to lung, hence not included in this study. The 
superior border of the PTV was located at the caudal aspect of the clavicular head. The lower PTV 
was shallower and treated with a lower energy electron beam, while the upper PTV was deeper 
and treated with a higher energy electron beam. This allowed dose to the heart to be minimized.  
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For these patients, the planned treatment used two abutted fields, each having different 
energies and irradiating separately the previously defined PTVs. Five plans were created for each 
patient; Plans 1,2, and 4 had the same PTVs (fields), illustrated in Figure 2.2, while Plans 3 and 5 
had the same PTVs (fields), illustrated in Figure 2.3. 
For Plans 1, 2, and 4 (Figure 2.2) the lower PTV extended from the inferior extent of the 
PTV to the farthest extent superior to the heart that could be treated using the lowest energy from 
the set of available discrete energies sufficient to treat the PTV anterior to the heart. For planning 
purposes, a 2 cm junction PTV was placed between the lower and upper PTVs. The upper PTV 
extended from the superior extent of the junction PTV to the supraclavicular PTV, which has an 
inferior border at the caudal aspect of the clavicular head. The lower PTV, junction PTV, and 
upper PTV together comprised the chest wall PTV used to evaluate plan quality, also referred to 
as the PTV Evaluate. The lower PTV was treated with the lower field, which had a 1.5 cm lateral 
expansion, a 2.0 cm inferior expansion, and a 1 cm superior expansion of the lower PTV. The 
upper PTV was treated with the upper field, which had a 1.5 cm lateral expansion, a 1 cm inferior 
expansion, and a 2.0 cm superior expansion of the upper PTV. 
For Plans 3 and 5 (Figure 2.3), the lower PTV extended from the inferior extent of the PTV 
to the superior extent of the heart. The selected energy is the lowest from a set of available 
continuous energies sufficient to treat the PTV superficial to the heart. For planning purposes, a 2 
cm junction was placed between the lower and upper PTVs. The upper PTV extended from the 
superior extent of the junction PTV (PTV Evaluate) to the supraclavicular region, which has an 
inferior border at the caudal aspect of the clavicular head. The lower PTV, junction, and upper 
PTV together comprised the PTV used to evaluate plan quality, also referred to as the Chest Wall 
PTV. The lower PTV was treated with the lower field, which had a 1.5 cm lateral expansion, a 2.0 
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cm inferior expansion, and a 1 cm superior expansion of the lower PTV. The upper PTV was 
treated with the upper field, which had a 1.5 cm lateral expansion, a 1 cm inferior expansion, and 
a 2.0 cm superior expansion of the upper PTV.  
 
Figure 2.2. Schematic of the PTVs and fields for Plans 1,2, and 4 for each patient. For these plans 
the superior border of the lower PTV is at the farthest superior extent that can be covered with the 
lower energy beam. The chest wall PTV (PTV Evaluate) is comprised of the upper PTV (orange 
region outlined by dashed lines), the lower PTV (green region outlined by dashed lines), and the 
intervening junction PTV (outlined by dashed lines). Lower field is light green region outlined by 
solid black line; upper field is light orange region outlined by solid black line. 
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Figure 2.3. Schematic of PTVs and fields for Plans 3 and 5 for each patient in Patient Set 2. For 
these plans the superior border of the lower PTV is at the superior edge of the heart. Assuming 
availability of beams with continuous energy, Plans 3 and 5 beams are flattened using dual 
scattering foils and scanned beams, respectively. The chest wall PTV (PTV Evaluate) is comprised 
of the upper PTV (orange region outlined by dashed lines), the lower PTV (green region outlined 
by dashed lines), and the intervening junction PTV (outlined by dashed lines). Lower field is light 
green region outlined by solid black line; upper field is light orange region outlined by solid black 
line. 
2.1.4. Electron beam arrangements for Patient Set 1 
For Patient Set 1 an SSD of 105 cm was used, and the gantry angle was selected so the 
beam central axis was approximately perpendicular to the distal PTV surface, typical of BECT 
plans, which resulted in a left, anterior, oblique field. The beam parameters (i.e. gantry angles, 
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SSD, and field shape) were determined in Pinnacle3 and exported to p.d for use during bolus 
design. 
2.1.5. Electron beam arrangements for Patient Set 2 
For Patient Set 2, each plan consisted of three beams, one lower energy beam that covered 
the lower field, and two higher energy beams covered the upper field. The two upper fields were 
identical except for their lower edges, which were feathered so that their composite penumbra 
closely matched that of the lower field, maximizing dose homogeneity in the abutment region. All 
three beams shared a common isocenter and a common virtual source, i.e. common beam central 
axis. Each beam had a source-to-surface distance (SSD) of 105 cm along the common central axis, 
typically used to prevent collisions between the electron applicator and electron bolus. As was the 
case for Patient Set 1, the gantry angle was selected so that the beam central axis was 
approximately perpendicular to the distal PTV surface, typical of BECT treatment plans. The beam 
parameters (i.e. gantry angles, SSD, and field shape) were determined in Pinnacle3 and exported 
to p.d for use during bolus design. 
2.1.5.1. Upper field edge feathering for dose homogeneity at abutment of high and low energy 
fields 
Perfect penumbra matching between the upper and lower fields was impossible due to the 
different beam energies, as well as patient surface irregularities. To mitigate hot and cold spots, 
edge feathering of the upper (higher) energy beams was used. Figure 2.4 illustrates the need for 
edge feathering by using CW2 fields in water as an example, and Figure 2.5 illustrates how edge 
feathering was implemented in this study to improve dose homogeneity in the abutting region. 
Two identical copies of the upper field were created, then the inferior borders of the fields were 
shifted +/- Δ, where Δ depended on six factors: beam energy, PTV depth (z), and distance between 
the collimator and bolus surface (L0) for the lower and upper fields. These factors are illustrated 
24 
in Figure 2.6. The parameters used to determine Δ for patient plans in Patient Set 2 are shown in 
Table 2.1.  
The optimal edge feathering parameter, Δ, was determined by matching the penumbra of 
the lower and upper fields. This was done by minimizing the square of the residuals between the 
relative intensity functions for the lower field, 𝑓(𝑥), and for the upper field, (𝑔+Δ(𝑥) +
𝑔−Δ(𝑥))/2, where 𝑓 and 𝑔 were found by following: 
𝑓(𝑥) =
1
2
[erf (
𝑤0
2
−𝑥
√2𝜎𝑥
) + erf (
𝑤0
2
+𝑥
√2𝜎𝑥
)]   
𝑔±Δ(𝑥) =
1
2
[erf (
𝑤0±Δ
2
−𝑥
√2𝜎𝑥
) + erf (
𝑤0±Δ
2
+𝑥
√2𝜎𝑥
)] . 
Here, x is the distance from the center of the upper field to the edge of the abutting edge. 𝑤0 and 
𝜎𝑥 are patient dependent, depending on the energy and geometry of each of the abutted fields, 
illustrated in Figure 2.6. The latter is given by 
𝜎𝑥
2 = (𝑧 + 𝐿0)
2𝜎𝜃𝑥
2 + 𝑎2(𝑧) 
𝑧 is the distance from the bolus surface to a depth equal to half the chest wall PTV thickness below 
the skin surface at the abutment location, 𝐿0 is the distance from the bottom edge of the electron 
cutout/applicator to the bolus surface, and 𝑎2(𝑧) is the RMS spread of the lateral distribution of 
electron beams incident on the bolus at depth (z) equal to the distance from the bolus surface to 
half the chest wall PTV thickness in the patient. 𝑎2(𝑧) was determined using the formalism of 
Werner et al.44 The optimization of Δ was determined using the L2 norm in a MATLAB program 
developed for this study. 
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Figure 2.4. Off-axis dose distributions for two abutting fields are shown for CW2. (a) Without 
feathering, there is a +/- 11% dose heterogeneity. (b) When feathering the lower border of the 
upper field, the dose heterogeneity has been reduced to +/- 4%. See Table 2.1 for values of six 
parameters. 
 
(
a) 
(
b) 
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Figure 2.5. Beam’s eye view illustrating feathering lower edge of the upper field (±Δ) abutted to 
lower field. 
 
Figure 2.6. Side view illustrating six parameters that affect Δ when determining feathering of upper 
field penumbra to match that of lower field. 
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Table 2.1. Parameters used to calculate Δ for Patient Set 2. All values are shown for Plan 1, which 
has discrete energy spacing and uses scattered electron beams. 
Patient 
Lower 
Energy 
(MeV) 
Lower 
R90 
(cm) 
Lower 
L0 
(cm) 
Lower 
z (cm) 
Upper 
Energy 
(MeV) 
Upper 
R90 
(cm) 
Upper 
L0 
(cm) 
Upper 
z (cm) 
Δ 
(cm) 
CW2 13.0 4.0 6.9 3.6 16.2 5.0 5.9 4.6 0.7 
CW4 16.2 5.0 8.0 4.0 21.3 6.0 7.0 5.0 0.8 
CW7 16.2 5.0 6.1 4.5 21.3 6.0 5.1 5.5 0.7 
CW8 13.0 4.0 7.6 3.2 16.2 5.0 6.6 4.2 0.6 
 
2.1.6. Energy Selection for Different Plans 
Table 2.2 lists R90 and R90-10 values for the energies available on the Elekta Infinity 
(scattered beams), and Table 2.3 shows the R90 and R90-10 values for R90 values corresponding to 
the Elekta Infinity for the Therac 20 (scanned beam). These discrete energies were used to create 
and evaluate treatment plans with discrete energy spacing.  
For each patient, either four plans (Pans 1,2,4,5) were created (Patient Set 1) or five plans 
(Plans1-5) were created (Patient Set 2). Described as follows, the different plans investigated the 
effects of scattered versus scanned beams as well as the effects of continuous energy spacing. 
Table 2.2. Available electron energies on the Elekta Infinity at MBPCC, as well as corresponding 
R90 and R90-10 values in water. In the case where the depth of the target falls between two R90 
values, the higher energy must be used. Continuously spaced electron energies will prevent 
unnecessary additional dose to distal normal tissue.
 Nominal Energy (MeV) Ep,0 (MeV) R90 (cm) R90-10 (cm) 
7 7.0 2.0 1.4 
9 8.4 2.5 1.7 
10 9.9 3.0 1.9 
11 11.4 3.5 2.1 
13 13.0 4.0 2.4 
16 16.2 5.0 3.0 
20 21.3 6.0 4.4 
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Table 2.3. Beam parameters of Therac 20 for R90 values corresponding to the same R90 values as 
available electron energies on the Elekta Infinity. Also shown are the corresponding Ep,0 and R90-
10 values. In the case where the depth of the target falls between two R90 values, the higher energy 
must be used. Continuously spaced electron energies will prevent unnecessary additional dose to 
distal normal tissue. 
Nominal Energy (MeV) Ep,0 (MeV) R90 (cm) R90-10 (cm) 
7 6.5 2.0 1.1 
9 8.9 2.5 1.4 
10 9.4 3.0 1.5 
11 10.8 3.5 1.8 
12 12.1 4.0 2.0 
15 15.1 5.0 2.4 
18 18.3 6.0 3.0 
 
Plan 1, Scattered, Discrete Energy Beams: 
For Plan 1, Patient Set 1, the PTV and field were planned as shown in Figure 2.1. The 
minimum commercially available energy (from Table 2.2), whose 90% dose surface (R90) could 
sufficiently cover the entire PTV, was selected. 
For Plan 1, Patient Set 2, the PTVs and fields were planned as shown in Figure 2.2. The 
minimum commercially available Elekta scattered beam energy (see Table 2.2) for each beam, 
whose 90% dose surface (R90) could sufficiently cover the lower or upper PTVs, was selected. 
Plan 2, Scattered, Discrete and Continuous Energy Beams: 
 For Patient Set 1 no Plan 2 was created, as there was no upper field. For Plan 2, Patient Set 
2, the PTVs and fields were created as shown in Figure 2.2. The lower field was planned using the 
same field as in Plan 1. Different from Plan 1, the upper field was planned with the minimum 
energy, assuming continuous energy beams, whose 90% dose surface (R90) could sufficiently 
cover the upper PTV, assuming availability of continuous energy spacing. Both fields were treated 
with scattered electron beams. 
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Plan 3, Scattered, Continuous Energy Beams: 
For Plan 3, Patient Set 1, the PTV and field were planned as shown in Figure 2.1. The PTV 
was planned using a single beam with the minimum energy whose 90% dose surface (R90) could 
sufficiently cover the upper PTV, assuming availability of continuous energy spacing for scattered 
Elekta beams.  
For Plan 3, Patient Set 2, the PTVs and fields were created as shown in Figure 2.3. The 
lower field was planned using the minimum energy whose 90% dose surface (R90) could 
sufficiently cover the lower PTV, assuming availability of continuous energy spacing for scattered 
Elekta beams. The upper field was treated with the lowest energy, whose 90% dose surface (R90) 
could sufficiently cover the upper PTV, assuming availability of continuous energy spacing for 
scattered Elekta beams.  
Plan 4, Scanned, Discrete Energy Beams: 
For Plan 4, Patient Set 1, the PTV and field were planned as shown in Figure 2.1. The PTV 
was planned using a single beam by selecting the minimum discrete beam energy, whose 90% 
dose surface (R90) could sufficiently cover the entire PTV. The single scanned beam energy was 
selected from Therac 20 scanned electron beams energies, assumed to have the same discrete R90 
values as commercially available Elekta beams (from Table 2.3). 
For Plan 4, Patient Set 2, the PTVs and fields were created as shown in Figure 2.2. 
Assuming Therac 20 scanned electron beams energies, having the same discrete R90 values as 
commercially available Elekta beams (from Table 2.2), a plan was developed the same as done 
using scattered beams in Plan 1. That is, the minimum energy beams whose 90% dose surface 
(R90) could sufficiently cover the lower and upper PTVs, were selected.  
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Plan 5, Scanned, Continuous Energy Beams: 
For Plan 5, Patient Set 1, the PTV and field were planned as shown in Figure 2.1. The 
single field was treated with the lowest energy whose 90% dose surface (R90) could sufficiently 
cover the PTV, assuming continuous energy spacing and scanned electron beams. 
For Plan 5, Patient Set 2, the PTVs and fields were created as shown in Figure 2.3. This 
plan was developed using the same methods as detailed in Plan 3 with the exception that Therac 
20 scanned beams with continuous beam energies rather than Elekta scattered beams with 
continuous energy were assumed available and used. That is, the lower field was planned with the 
minimum energy whose 90% dose surface (R90) could sufficiently cover the lower PTV, and the 
upper field was treated with the minimum energy whose 90% dose surface (R90) could sufficiently 
cover the upper PTV.  
The parameters for each plan for Patient Set 1 are summarized in Table 2.4. The parameters 
for each plan for Patient Set 2 are summarized in Table 2.5. 
Table 2.4. Summary of energy availability for each of the four plans for patients in Patient Set 1. 
See geometry for plans in Figure 2.1.  
Plan Energy Spacing Beam Flattening 
1 Discrete Scattered 
2 N/A N/A 
3 Continuous Scattered 
4 Discrete Scanned 
5 Continuous Scanned 
 
Table 2.5. Summary of energy availability for each of the five plans for each patient in Patient Set 
2. See geometry for plans 1,2 and 4 in Figure 2.2.  
Plan 
Energy Spacing: 
Lower PTV 
Energy Spacing: 
Upper PTV 
Beam Flattening 
1 Discrete Discrete Scattered 
2 Discrete Continuous Scattered 
3 Continuous Continuous Scattered 
4 Discrete Discrete Scanned 
5 Continuous Continuous Scanned 
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2.1.7. Design of Bolus and Intensity Modulation for IM-BECT Patient Plans 
Bolus and intensity modulations for each field were designed using a research version of 
p.d, which included intensity modulation.42 Each bolus was designed using a set of operators from 
Low et al.38 that were clinically available and manually optimized to fulfill the design goals of 
circumscribing the PTV with the 90% dose surface. Intensity modulation was designed to improve 
dose homogeneity in the PTV. Dose calculations in p.d were performed using a 3-dimentional 
implementation of the pencil beam redefinition algorithm (PBRA)45–47 with intensity 
modulation.34  
 Operators to create the bolus fall into three categories: bolus creation operators, bolus 
modification operators, and bolus extension operators. A description of these operators can be 
found in Appendix A. For a specific patient, the sequence of bolus operators for each field are 
identical for each plan. The operators used for each patient in Patient Set 1 are almost identical, 
with slight variation. Likewise, the operators used for each patient in Patient Set 2 are almost 
identical, with slight variation. The operator sequences for Patient Set 1 and Patient Set 2 are listed 
in Table 2.6 and Table 2.7, respectively. 
Table 2.6. Summary of bolus design operator sequences for Patient Set 1. See Appendix A for 
explanation of operators. 
Number PTV Field 
1 Create (1.5 cm) 
2 Truncate 
3 Smooth (1,1) 
4 IM (1.1) 
5 Isodose shift (90%) 
6 Smooth (1,1) 
7 Specified shift (-0.2 cm) 
8 Isodose shift (90%) 
9 Smooth (1,0.5) 
10 IM (1.0) 
32 
Table 2.7. Summary of bolus design operator sequences for Patient Set 2. See Appendix A for 
explanation of operators. 
Number Lower Field Upper Field (shifted +Δ) Upper Field (shifted -Δ) 
1 Create (1.5 cm) Create (0.75 cm) Create (0.75 mm) 
2 Truncate Truncate Truncate 
3 Smooth (1,1) Smooth (1,1) Smooth (1,1) 
4 IM (1.1) Isodose shift (90%) Specified Shift (-0.8 cm) 
5 Isodose shift (90%) Smooth (1,1)  
6 Smooth (1,1) IM (1.1)  
7 Specified shift (-0.2 cm)   
8 Isodose shift   
9 Smooth (1,0.5)   
10 IM (1.0)   
 
For the lower PTV of plans in Patient Set 2, a bolus is created with an inner margin of 1.5 cm 
(border between the outer portion of bolus created and outer edge of PTV). Then the truncation 
operator was used to minimize the height of the rim of the bolus outside the treatment area, as to 
avoid collision between the electron applicator and bolus. The creation operator creates height 
irregularities in the bolus surface since the distal surface of the PTV is not smooth, potentially 
causing hot and cold spots in the PTV. So, the next step used a smoothing operator to reduce 
surface irregularities on the proximal side of the bolus. Intensity modulation further reduced the 
hot and cold spots in the PTV. Next, an isodose shift was used to shift the 90% isodose surface 
towards the distal PTV surface. The isodose shift operator is a one-dimensional operator, which 
means it only considers the difference between the physical distal target depth and the 90% dose 
line along each fan line diverging from the source. However, because electrons scatter laterally, 
multiple applications of the isodose shift operator were needed for larger targets. Following each 
isodose shift operator, the smoothing operator was applied to reduce the hot and cold hots in the 
PTV. Following the first isodose shift –smoothing operator sequence, to better visualize PTV 
coverage, a specified shift of 0.2 cm was used to shift the 90% dose surface towards the distal 
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surface of the PTV (though this step does not influence the final bolus design). The final steps 
were isodose shift, smooth, and intensity modulation to improve the homogeneity of the dose 
distribution. This was the baseline set of operators used for all patients in Patient Set 1. However, 
this baseline was adjusted on a patient by patient basis to achieve more optimal bolus. For plans 
in Patient Set 2, the bolus design operator sequence for the lower field was identical to the sequence 
used for Patient Set 1. 
2.1.8. Normalization and Summation of Dose 
Dose was normalized in p.d for each field such that 100% corresponded to the given dose. 
Given dose is defined as the maximum central axis dose (Dmax) in a water phantom at the planned 
SSD for the rectangular field with least area that circumscribes the treatment field. The SSD is the 
distance from a point 100 cm upstream of isocenter (nominal source location) to the surface of the 
bolus along central axis of the beam. Because central axis was in the abutment region for our 
beams in Patient Set 2, its SSD was not necessarily representative of that at the center of the field; 
therefore, this required that the dose be renormalized so that the mean value of the dose along the 
depth of maximum dose was 100%. This was achieved visually by achieving intermittent islands 
of the 100% isodose lines in the transverse plane near the field center. These normalization factors 
ranged from 0.97 to 1.03 for all twenty plans generated in Patient Set 2. Similar normalization was 
used for plans in Patient Set 1 and ranged from 0.99 to 1.01. 
After finalizing the beams in p.d for each of the plans for each patient, the dose distributions 
for each plan were exported to MIM for summation and conversion from percent dose to dose in 
Gy. For Patient Set 2, the composite percent dose distribution equaled the percent dose distribution 
for the lower field plus the sum of 50% of the percent dose distributions (±Δ) for the upper fields 
(see Figure 2.5), i.e. equal weighting given to both the + Δ and – Δ fields. Percent doses were 
converted to dose by prescribing 50 Gy to the 90% contour, i.e. multiplying all values by (50 
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Gy/90%). The summed dose distributions for both Patient Set 1 and Patient Set 2 are shown in the 
isodose distributions in Appendix B, where 100%=55.5 Gy. The isodose distributions were also 
created in MIM. 
Finally, for comparing dose distributions for each plan of a single patient, each plan’s 
composite dose distribution was scaled relative to that of Plan 1, so all had the same PTV D50, that 
is the same dose value for 50% PTV coverage. This scaling was chosen because Plan 1 is the 
currently clinically available planning strategy; however, because D50 values of all plans were 
within a few percent, this scaling had little impact on the results and conclusions.  
2.2. Aim 2—Physical and Biological Dose Metrics for Plans  
2.2.1. Dose and Biological Metrics 
The cumulative DVHs for the heart, lungs, and PTV were extracted from MIM and 
imported to MATLAB, where an in-house script was used to determine the following dose and 
biological metrics. 
(1) PTV Metrics: 
a. D97%-Dose given to 97% of PTV volume  
b. Dmax-maximum dose to PTV 
c. Dmean-mean dose to PTV 
d. V47.5 Gy-volume of PTV receiving 47.5 Gy (95% of 50 Gy prescription) 
(2) Heart Metrics: 
a. Dmin-minimum dose to heart 
b. Dmax-maximum dose to heart 
c. Dmean-mean dose to heart 
d. V22.5 Gy-volume of heart receiving 22.5 Gy 
e. V30 Gy-volume of heart receiving 30 Gy 
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f. NTCP-normal tissue complication probability 
(3) Lung Metrics: 
a. Dmin-minimum dose to lungs 
b. Dmax-maximum dose to lungs 
c. Dmean-mean dose to lungs 
d. V20 Gy-volume of heart receiving 30 Gy 
e. NTCP-normal tissue complication probability 
f. SCCPlin-Secondary cancer complication probability, linear model 
g. SCCPlin-exp-Secondary cancer complication probability, linear-exponential 
model 
2.2.2. NTCP-Lungs 
NTCP values for the lungs were calculated using the Lyman-Kutcher-Burman (LBK) 
model.48, 49 The endpoint, which was used in the present study, was grade two radiation 
pneumonitis or higher, whose model follows: 
𝑁𝑇𝐶𝑃 =  
1
√2𝜋
∫ 𝑒
−𝑥2
2 𝑑𝑥
𝑡
−∞
, 
where 
𝑡 =
𝐸𝑈𝐷−𝑇𝐷50
𝑚∗𝑇𝐷50
, 
and 
𝐸𝑈𝐷 = (∑ 𝐷
𝑖
1
𝑛 𝑉𝑖
𝑉𝑡𝑜𝑡
𝑖 )
𝑛
. 
The definitions and values of the various parameters are found in Table 2.8. 
. 
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Table 2.8. Parameters for computing lung NTCP (from Seppenwoolde et al., 200348) 
Parameter Definition/ Value 
𝐷𝑖 dose per fraction to the sub-volume 𝑖 
𝑉𝑖 volume irradiated to dose 𝐷𝑖 
𝑉𝑡𝑜𝑡 total volume of lung 
𝑚 Slope of the dose-response curve, 0.37 
𝐸𝑈𝐷 
Dose from a non-uniform dose distribution that results in 
the same NTCP as a non-uniform dose distribution 
𝑇𝐷50 
Dose that would cause a 50% risk of complication if 
given uniformly, 30.8 Gy 
𝑛 0.99 
 
2.2.3. NTCP-Heart 
The NTCP for the whole heart was calculated using Kallman’s relative seriality model, 
which takes into account both the parallel and serial arrangements of functional subunits within 
the heart.50 When finding the NTCP, cardiac mortality was used as the endpoint, i.e. 
𝑁𝑇𝐶𝑃 = {1 − ∏ (1 − 𝑃(𝐷𝑖)
𝑠)𝑉𝑖𝑖 }
1
𝑠  , 
where 
𝑃(𝐷𝑖) = 2
−𝑒
𝑒𝛾(1−
𝐷𝑖
𝐷50
)
 . 
The definitions and values of the various parameters are found in Table 2.9. 
Table 2.9. Parameters for computing heart NTCP (from Gagliardi et al., 200110) 
Parameter Definition/ Value 
𝐷𝑖 dose to the sub-volume 𝑖 
𝑉𝑖 volume irradiated to dose 𝐷𝑖 
𝑠 Ratio of serial function subunits to total functional subunits, 1 
𝑇𝐷50 
Dose that would cause a 50% risk of complication if given 
uniformly, 52.3 Gy 
𝛾 Maximum relative slope of the dose-response curve, 1.28 
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2.2.4. SCCP-Lungs 
In addition to NTCP, the secondary cancer complication probability (SCCP) was calculated 
for the lungs using two different models, the linear dose response model (SCCPlin) and the linear-
exponential dose response (SCCPlin-exp). Here, the Schneider model
51 was used, i.e. 
𝑆𝐶𝐶𝑃𝑙 =  Inorg 𝑂𝐸𝐷𝑜𝑟𝑔,𝑙𝑖𝑛𝑒𝑎𝑟 ,  
where 
OEDorg,linear =
1
𝑉𝑜𝑟𝑔
∑ 𝑉𝑖𝐷𝑖 𝑖 ,  
and 
𝑆𝐶𝐶𝑃𝑙𝑖𝑛−𝑒𝑥𝑝 =  Inorg 𝑂𝐸𝐷𝑜𝑟𝑔,𝑙𝑖𝑛𝑒𝑎𝑟−𝑒𝑥𝑝𝑜𝑛𝑒𝑛𝑡𝑖𝑎𝑙 , 
where 
OEDorg,linear−exponential =
1
𝑉𝑜𝑟𝑔
∑ 𝑉𝑖𝐷𝑖𝑒
−𝛼𝐷𝑖  𝑖 . 
The definitions and values of the various parameters are found in Table 2.10. 
Table 2.10. Parameters for computing lung SCCP (from Schneider et al., 200551) 
Parameter Definition/ Value 
𝛼 
Organ specific cell sterilization parameter, 0.085 
Gy-1 
𝐷𝑖  dose to the sub-volume 𝑖 
𝑉𝑖 volume irradiated to dose 𝐷𝑖 
𝑉𝑜𝑟𝑔 Volume to the total organ 
𝑂EDorg 
Dose from a non-uniform dose distribution that 
results in the same cancer incidence as a non-
uniform dose distribution 
𝐼𝑁𝑜𝑟𝑔 
Organ specific absolute cancer incidence as a 
percentage per gray, representing the lifetime risk 
for a residual lifetime expectancy of 50 years, 
1.68% per Gy 
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Chapter 3. Results 
Aim 1 and Aim 2 results are presented together for each of the seven patients studied. The 
first section below describes the beams comprising the treatment plans. The second section shows 
and compares dose distributions, dose metrics, and biological metrics for multiple plans for each 
patient.  
3.1. Description of Treatment Plans for Different Electron Beam Technologies 
Aim 1 results show the resulting treatment beams and dose distribution for each of the four or 
five treatment plans developed for each of the seven patients. Treatment planning results are 
described below, partitioned into the two patent data sets. Plans for Patient Set 1 (CW1, CW3, 
CW6) required only a single electron field. Plans for Patient Set 2 (CW2, CW4, CW7, CW8) 
required two electron fields (upper and lower). 
3.1.1. Treatment Planning Beam Parameters (Patient Set 2) 
Patient plans were developed in accordance with the methods described above. For Patient Set 
1 (CW1, CW3, CW6), the beam parameters for Plans 1-4 are listed in Table 3.1. 
Table 3.1. Summary of beam parameters for each patient and plan in Patient Set 1. 
Patient Plan 
Beam 
Type 
Energy 
Spacing 
Energy 
(MeV) 
R90 
(cm) 
Gantry 
Angle (°) 
CW1 
1 Scattered Discrete 21.3 6.0 
130 
3 Scattered Continuous 19.5 5.7 
4 Scanned Discrete 18.4 6.0 
5 Scanned Continuous 17.3 5.7 
       
CW3 
1 Scattered Discrete 13.0 4.0 
40 
3 Scattered Continuous 12.4 3.8 
4 Scanned Discrete 12.2 4.0 
5 Scanned Continuous 11.6 3.8 
       
CW6 
1 Scattered Discrete 16.2 5.0 
45 
3 Scattered Continuous 15.6 4.8 
4 Scanned Discrete 15.1 5.0 
5 Scanned Continuous 14.5 4.8 
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For patients in Patient Set 2 (CW2, CW4, CW7, and CW8) the PTVs were partitioned as 
illustrated in Figure 2.2 for Plans 1, 2, and 4, and in Figure 2.3 for Plans 3 and 5. The resulting 
beam energies (Ep,0), therapeutic ranges (R90), and beam angles of all five plans for each of the 
four patients are listed for the lower and upper fields in Table 3.2. 
Table 3.2. Summary of beam parameters for each patient and plan in Patient Set 2. 
Patient Plan 
Beam 
Type 
Energy 
Spacing 
Lower 
Field 
E 
(MeV) 
Lower 
Field 
R90 
(cm) 
Upper 
Field 
E 
(MeV) 
Upper 
Field 
R90 
(cm) 
 
Gantry 
Angle 
(°) 
 
 
Δ 
(cm) 
CW2 
1 Scattered Discrete 13.0 4.0 16.2 5.0 
38 0.7 
2 Scattered Discrete 13.0 4.0 15.9 4.9 
3 Scattered Continuous 13.0 4.0 15.9 4.9 
4 Scanned Discrete 12.2 4.0 15.1 5.0 
5 Scanned Continuous 12.2 4.0 14.8 4.9 
          
CW4 
1 Scattered Discrete 16.2 5.0 21.3 6.0 
150 0.8 
2 Scattered Discrete 16.2 5.0 21.3 6.0 
3 Scattered Continuous 16.2 5.0 21.3 6.0 
4 Scanned Discrete 15.1 5.0 18.4 6.0 
5 Scanned Continuous 15.1 5.0 18.4 6.0 
          
CW7 
1 Scattered Discrete 16.2 5.0 21.3 6.0 
50 0.7 
2 Scattered Discrete 16.2 5.0 21.3 6.0 
3 Scattered Continuous 16.2 5.0 21.3 6.0 
4 Scanned Discrete 15.1 5.0 18.4 6.0 
5 Scanned Continuous 15.1 5.0 18.4 6.0 
          
CW8 
1 Scattered Discrete 13.0 4.0 16.2 5.0 
40 0.6 
2 Scattered Discrete 13.0 4.0 15.6 4.8 
3 Scattered Continuous 11.1 3.4 15.6 4.8 
4 Scanned Discrete 12.2 4.0 14.5 4.8 
5 Scanned Continuous 10.5 3.4 14.5 4.8 
 
Also, for all five plans, the abutment region was managed by feathering the upper beam, as 
illustrated in Figure 2.6. A profile of the abutting scheme for CW2 is illustrated in Figure 2.4 and 
the resulting profiles for all four patients are plotted in Figure 3.1. They show the dose 
heterogeneity being reduced to less than ±6% in the abutment region of the PTV. 
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Figure 3.1. Feathering results for all four patients in Patient Set 2. (a) For CW2, Δ=0.7 cm which 
results in dose heterogeneities of +/-4%. (b) For CW4, Δ=0.8 cm which results in dose 
heterogeneities of +/-5% (c) For CW7, Δ=0.7 cm which results in dose heterogeneities of +/-6% 
(d) For CW8, Δ=0.6 cm which results in dose heterogeneities of +/-4%. 
For each plan three transverse and one sagittal-coronal oblique planar dose distributions 
are plotted over the CT images. Also, for each patient, DVHs for the PTV, heart, and lungs are 
plotted for each plan. Using the DVHs, dose and biologic metrics are calculated and compared in 
a single table. Dose metrics include: (1) PTV: D97% (Dose given to 97% of PTV volume), Dmax 
(maximum dose), Dmean (mean dose), and V47.5 Gy (relative volume of PTV receiving 47.5 Gy, or 
95% of the prescribed dose), (2) Heart: Dmin, Dmax, Dmean, V22.5 Gy (relative volume of heart 
receiving 22.5 Gy), and V30 Gy (relative volume of heart receiving 30 Gy), and (3) Lung: Dmin, 
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Dmax, Dmean, and V20 Gy (relative volume of lung receiving 20 Gy). Biological dose metrics include: 
(1) Heart: NTCP (normal tissue complication probability) and (2) Lung: NTCP, SCCPlin 
(secondary cancer complication probability, linear model), SCCPlin-exp (secondary cancer 
complication probability, linear-exponential model). 
3.2. Dose Distributions, DVHs, Dose Metrics, and Biological Metrics for All Plans for Each 
Patient 
Results are presented for three patients in Patient Set 1 (CW1, CW3, and CW6) and four 
patients in Patient Set 2 (CW2, CW4, CW7, and CW8). Results for Patient Set 1, for which there 
are four plans (Plan 1, Plan 3, Plan 4, and Plan 5 as detailed earlier), are shown first because they 
required only a single electron beam and are easier to compare and interpret. Results for Patient 
Set 2, for which there are five plans (Plan 1, Plan 2, Plan 3, Plan 4, and Plan 5 as detailed earlier), 
are shown second, as they required upper and lower fields, the upper having edge feathering, hence 
three electron beams. As such, these plans are more complex to compare and interpret. 
The trends indicated by the metrics above can be visualized by comparing the isodose plots 
for the four plans being compared. The PTV coverage is appreciated by viewing the PTV and the 
80% and 90% isodose lines. The heart dose is appreciated by comparing isodose lines in the dose 
falloff region, particularly the 40% isodose line that equals approximately 22.5 Gy, with the 
anterior heart in the sagittal-coronal oblique and two inferior planes demarcated on the former. 
Lung dose is appreciated by comparing isodose lines in the dose falloff region, particularly the 
40% isodose line that is just greater than 20 Gy, within the lung (superior to heart) in the sagittal-
coronal oblique and the superior plane demarcated on the former. For the remaining comparisons, 
the sagittal-coronal oblique plane and the transverse plane through mid-heart will be shown in the 
text, and isodose plots for their respective transverse planes through the region superior to the heart 
and through the inferior heart are plotted in Appendix B. 
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3.2.1. Result for Patient Set 1 
Treatment planning results for patients in Patient Set 1 (CW1, CW3, and CW6) are shown 
using isodose plots for three transverse planes and one sagittal-coronal oblique plane for Plans 1, 
3, 4, and 5. Inspection of these plots shows utilization of continuous rather than discrete energy 
beams usually resulted in lower beam energies. Because lower energy beams have a sharper dose 
falloff, this usually resulted in less normal tissue dose and lower complication probabilities. Also, 
utilization of scanned versus scattered electron beams, which results in sharper dose falloff, 
resulted in less normal tissue dose and lower complication probabilities. The combination of the 
two effects is greater than either alone and is illustrated by comparing Plan 1 (scattered, discrete 
energy beams) and Plan 5 (scanned beam, continuous energy beams), which represent the worst 
and best plans, respectively. 
3.2.1.1. Results for Patient CW1 
Treatment planning results for CW1 (Patient Set 1) include isodose plots for three 
transverse planes and one sagittal-coronal oblique plane for Plans 1, 3, 4, and 5. All such results 
are shown in Appendix B, and one sagittal-coronal oblique plane and one transverse plane for each 
plan are shown in Figure 3.2 to Figure 3.5. DVHs for PTV, heart, and lungs for each of the four 
plans were computed and plotted for comparison in Figure 3.6. Dose and biologic metrics 
computed from the DVHs are compared in Table 3.3. These results likely have some dependence 
on the location of the distal PTV surface, and for CW1 the distance between the distal edge of the 
PTV and the distal side of the chest wall (Δt) was 1.3 cm on central axis. 
PTV Coverage: Dose plots (Figure 3.2 to Figure 3.5) show that the 90% isodose lines 
closely cover the distal PTV surface, or in some locations the 80% isodose surface due to the 
jagged nature of the PTV. Most evident at the lateral edges of the PTV, coverage could be 
improved by increasing the lateral margin between the PTV and field edge or by a more realistic 
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PTV (smoother edges). The PTV DVHs are similar for all plans; V47.5 Gy values of the scanned 
beams are slightly less than those of the scattered beams. Maximum doses are less than 57 Gy 
(<103%). 
Effect of Scanned vs. Scattered Beams: Comparing Plan 1 (scattered, discrete energy 21.3 
MeV beam) and Plan 4 (scanned, discrete energy 18.4 MeV beam) showed that the scanned 
electron beam reduced (1) mean dose to the heart by 2.7 Gy (8.3 to 5.6 Gy) and (2) V20 Gy to the 
lung by 3.7% (17.2 to 13.5%). This resulted in reduced (1) NTCPheart by 0.2% (0.4 to 0.1%), (2) 
NTCPlungs by 0.01% (0. 02 to 0.01%), and (3) SCCPlin by 3.5% (14.4 to 10.8%). 
Comparing Plan 3 (scattered, continuous energy 19.5 MeV beam) and Plan 5 (scanned, 
continuous energy 17.3 MeV beam) showed that the scanned electron beam reduced (1) mean dose 
to the heart by 2.0 Gy (6.4 to 4.3 Gy) and (2) V20Gy to the lung by 3.4% (14.1 to 10.7%). This 
resulted in reduced (1) NTCPheart by 0.1% (0.2 to 0.1%), (2) NTCPlungs by 0.0% (0. 01 to 0.01%), 
and (3) SCCPlin by 3.1% (11.7 to 8.7%). 
Effect of Continuous vs. Discrete Beam Energies: The same data above can be used to 
evaluate the benefit of continuous versus discrete energy beams. Comparing Plan 1 (scattered, 
discrete energy 21.3 MeV beam) with Plan 3 (scattered, continuous energy 19.5 MeV beam) 
showed that continuous energy beams reduced (1) mean dose to the heart by 1.9 Gy (8.3 to 6.4 
Gy) and (2) V20Gy to the lung by 3.2% (17.2 to 14.1%). This resulted in reduced (1) NTCPheart by 
0.2% (0.4 to 0.2%), (2) NTCPlungs by 0.01% (0. 02 to 0.01%), and (3) SCCPlin by 2.6% (14.4% to 
11.7%). 
Comparing Plan 4 (scanned, discrete energy 18.4 MeV beam) with Plan 5 (scanned, 
continuous energy 17.3 MeV beam) showed that continuous energy beams reduced (1) mean dose 
to the heart by 1.3 Gy (5.6 to 4.3 Gy) and (2) V20Gy to the lung by 2.8% (13.5 to 10.7%). This 
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resulted in reduced (1) NTCPheart by 0.09% (0.14 to 0.05%), (2) NTCPlungs by 0.00% (0. 01 to 
0.01%), and (3) SCCPlin by 2.1% (10.8% to 8.7%). 
Effect of Scanned, Continuous Energy Beams vs. Scattered, Discrete Energy Beams: The 
greatest plan improvement was comparing Plan 1 (scattered, discrete energy 21.3 MeV beam), 
current technology, with Plan 5 (scanned, continuous energy 17.3 MeV beam), possible future 
technology, which reduced (1) mean dose to the heart by 3.9 Gy (8.3 to 4.3 Gy) and (2) V20Gy to 
the lung by 6.5% (17.2 to 10.7%). This resulted in reduced (1) NTCPheart by 0.3% (0.4 to 0.05%), 
(2) NTCPlungs by 0.01% (0.02 to 0.01%), and (3) SCCPlin by 5.7% (14.4% to 8.7%). 
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Figure 3.2. Sagittal and axial images of CW1, Plan 1. CW1 (Patient Set 1) was planned using 
scattered electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique 
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane 
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Bolus is 
shaded blue, and PTV is outlined in white. Key shows dose values. 
 
46 
 
Figure 3.3. Sagittal and axial images of CW1, Plan 3. CW1 (Patient Set 1) was planned using 
scattered electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal, 
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in 
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique 
plane. Bolus is shaded blue, and PTV is outlined in white. Key shows dose values. 
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Figure 3.4. Sagittal and axial images of CW1, Plan 4. CW1 (Patient Set 1) was planned using 
scanned electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique 
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane 
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Bolus is 
shaded blue, and PTV is outlined in white. Key shows dose values. 
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Figure 3.5. Sagittal and axial images of CW1, Plan 5. CW1 (Patient Set 1) was planned using 
scanned electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal, 
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in 
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique 
plane. Bolus is shaded blue, and PTV is outlined in white. Key shows dose values. 
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Figure 3.6. Comparison of cumulative DVH plots for CW1 (Patient Set 1) Plans. DVH plots for 
PTV, heart, and lung are compared for Plans 1, 3, 4, and 5, as indicated in key. 
Table 3.3. Comparison of metrics for CW1 (Patient Set 1) Plans. Dose metrics are shown for PTV, 
heart, and lungs. NTCP and SCCP values are shown for heart and lungs. 
   Plan 1 Plan 3 Plan 4 Plan 5 
PTV 
D97% (Gy) 46.9 46.4 46.2 45.9 
V47.5 Gy (%) 96.2 95.3 94.6 94.1 
Max dose (Gy) 56.6 56.9 56.7 56.7 
Mean dose (Gy) 51.9 51.8 51.7 51.7 
Std Dev (Gy) 2.2 2.5 2.6 2.8 
      
Heart 
V22.5 Gy (%) 10.4 5.7 4.9 2.3 
V30 Gy (%) 3.1 0.9 0.8 0.1 
Min dose (Gy) 1.3 1.1 0.7 0.5 
Max dose (Gy) 40.9 37.9 38.2 34.1 
Mean dose (Gy) 8.3 6.4 5.6 4.3 
Std Dev (Gy) 8.3 7.2 7.2 6.0 
NTCP (%) 0.4 0.2 0.1 0.1 
     
Lungs 
V20 Gy (%) 17.2 14.1 13.5 10.7 
Min dose (Gy) 0.0 0.0 0.0 0.0 
Max dose (Gy) 47.1 45.4 49.0 43.8 
Mean dose (Gy) 8.6 7.0 6.5 5.2 
Std Dev (Gy) 11.9 10.7 10.7 9.4 
NTCP (%) 0.02 0.01 0.01 0.01 
SCCPlin (%) 14.4 11.7 10.8 8.7 
SCCPlin-exp (%) 3.4 3.0 2.6 2.2 
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3.2.1.2. Results for Patient CW3 
Treatment planning results for CW3 (Patient Set 1) include isodose plots for three 
transverse planes and one sagittal-coronal oblique plane for Plans 1, 3, 4, and 5. All such results 
are shown in Appendix B, and one sagittal-coronal oblique plane and one transverse plane for each 
plan are shown in Figure 3.7 to Figure 3.10. DVHs for PTV, heart, and lungs for each of the four 
plans were computed and plotted for comparison in Figure 3.11. Dose and biologic metrics 
computed from the DVHs are compared in Table 3.4. These results likely have some dependence 
on the location of the distal PTV surface, and for CW3 the distance between the distal edge of the 
PTV and the distal side of the chest wall (Δt) was 1.1 cm on central axis. 
PTV Coverage: Dose plots (Figure 3.7 to Figure 3.10) show that the 90% isodose lines 
closely cover the distal PTV surface, or in some locations the 80% isodose surface due to the 
jagged nature of the PTV. Most evident at the lateral edges of the PTV, coverage could be 
improved by increasing the lateral margin between the PTV and field edge or by a more realistic 
PTV (smoother edges). The PTV DVHs are similar for all plans; V47.5 Gy values of the scanned 
beams are slightly less than those of the scattered beams. Maximum doses are less than 59 Gy 
(<106%). 
Effect of Scanned vs. Scattered Beams: Comparing Plan 1 (scattered, discrete energy 13.0 
MeV beam) and Plan 4 (scanned, discrete energy 12.2 MeV beam) showed that the scanned 
electron beam reduced (1) mean dose to the heart by 0.2 Gy (4.3 to 4.1 Gy) and (2) V20 Gy to the 
lung by 1.7% (15.8 to 14.1%). This resulted in reduced (1) NTCPheart by 0.05% (0.1 to 0.05%), (2) 
NTCPlungs by 0.00% (0.01 to 0.01%), and (3) SCCPlin by 1.3% (11.8 to 10.5%). 
Comparing Plan 3 (scattered, continuous energy 12.4 MeV beam) and Plan 5 (scanned, 
continuous energy 11.6 MeV beam) showed that the scanned electron beam reduced (1) mean dose 
to the heart by 0.0 Gy (3.7 to 3.7 Gy) and (2) V20Gy to the lung by 2.0% (14.5 to 12.5%). This 
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resulted in reduced (1) NTCPheart by 0.03% (0.06 to 0.03%), (2) NTCPlungs by 0.0% (0.1 to 0.1%), 
and (3) SCCPlin by 1.3% (10.7 to 9.4%). 
Effect of Continuous vs. Discrete Beam Energies: The same data above can be used to 
evaluate the benefit of continuous versus discrete energy beams. Comparing Plan 1 (scattered, 
discrete energy 13.0 MeV beam) with Plan 3 (scattered, continuous energy 12.4 MeV beam) 
showed that continuous energy beams reduced (1) mean dose to the heart by 0.6 Gy (4.3 to 3.7 
Gy) and (2) V20Gy to the lung by 1.4% (15.8 to 14.5%). This resulted in reduced (1) NTCPheart by 
0.04% (0.1 to 0.06%), (2) NTCPlungs by 0.00% (0.01 to 0.01%), and (3) SCCPlin by 1.1% (11.8% 
to 10.7%). 
Comparing Plan 4 (scanned, discrete energy 12.2 MeV beam) with Plan 5 (scanned, 
continuous energy 11.6 MeV beam) showed that continuous energy beams reduced (1) mean dose 
to the heart by 0.4 Gy (4.1 to 3.7 Gy) and (2) V20Gy to the lung by 1.6% (14.1 to 12.5%). This 
resulted in reduced (1) NTCPheart by 0.02% (0.05 to 0.03%), (2) NTCPlungs by 0.0% (0.1 to 0.1%), 
and (3) SCCPlin by 1.1% (10.5% to 9.4%). 
Effect of Scanned, Continuous Energy Beams vs. Scattered, Discrete Energy Beams: The 
greatest plan improvement was comparing Plan 1 (scattered, discrete energy 13.0 MeV beam), 
current technology, with Plan 5 (scanned, continuous energy 11.6 MeV beam), possible future 
technology. This reduced (1) mean dose to the heart by 0.6 Gy (4.3 to 3.7 Gy) and (2) V20Gy to the 
lung by 3.3% (15.8 to 12.5%). This resulted in reduced (1) NTCPheart by 0.07% (0.1 to 0.03%), (2) 
NTCPlungs by 0.00% (0.01 to 0.01%), and (3) SCCPlin by 2.4% (11.8% to 9.4%). 
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Figure 3.7. Sagittal and axial images of CW3, Plan 1. CW3 (Patient Set 1) was planned using 
scattered electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique 
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane 
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Bolus is 
shaded blue, and PTV is outlined in white. Key shows dose values. 
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Figure 3.8. Sagittal and axial images of CW3, Plan 3. CW3 (Patient Set 1) was planned using 
scattered electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal, 
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in 
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique 
plane. Bolus is shaded blue, and PTV is outlined in white. Key shows dose values. 
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Figure 3.9. Sagittal and axial images of CW3, Plan 4. CW3 (Patient Set 1) was planned using 
scanned electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique 
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane 
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Bolus is 
shaded blue, and PTV is outlined in white. Key shows dose values. 
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Figure 3.10. Sagittal and axial images of CW3, Plan 5. CW3 (Patient Set 1) was planned using 
scanned electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal, 
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in 
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique 
plane. Bolus is shaded blue, and PTV is outlined in white. Key shows dose values. 
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Figure 3.11. Comparison of cumulative DVH plots for CW3 (Patient Set 1) Plans. DVH plots for 
PTV, heart, and lung are compared for Plans 1, 3, 4, and 5, as indicated in key. 
Table 3.4. Comparison of metrics for CW3 (Patient Set 1) Plans. Dose metrics are shown for PTV, 
heart, and lungs. NTCP and SCCP values are shown for heart and lungs. 
  Plan 1 Plan 3 Plan 4 Plan 5 
PTV 
D97% (Gy) 45.4 44.9 44.8 44.4 
V47.5 Gy (%) 93.2 92.2 91.7 91.0 
Max dose (Gy) 58.3 58.8 58.6 58.6 
Mean dose (Gy) 51.6 51.6 51.6 51.5 
Std Dev (Gy) 2.7 2.8 2.9 3.0 
      
Heart 
V22.5 Gy (%) 3.4 2.5 2.2 1.5 
V30 Gy (%) 0.5 0.2 0.2 0.0 
Min dose (Gy) 0.7 0.7 0.0 0.1 
Max dose (Gy) 36.6 34.1 35.0 32.7 
Mean dose (Gy) 4.3 3.7 4.1 3.7 
Std Dev (Gy) 6.3 5.8 5.4 4.9 
NTCP (%) 0.1 0.1 0.1 0.03 
      
Lungs 
V20 Gy (%) 15.8 14.5 14.1 12.5 
Min dose (Gy) 0.0 0.0 0.0 0.0 
Max dose (Gy) 46.7 46.5 46.4 46.3 
Mean dose (Gy) 7.0 6.4 6.2 5.6 
Std Dev (Gy) 11.6 11.1 11.0 10.3 
NTCP (%) 0.0 0.0 0.0 0.0 
SCCPlin (%) 11.8 10.7 10.5 9.4 
SCCPlin-exp (%) 2.3 2.1 2.1 2.0 
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3.2.1.3. Results for Patient CW6 
Treatment planning results for CW6 (Patient Set 1) include isodose plots for three 
transverse planes and one sagittal-coronal oblique plane for Plans 1, 3, 4, and 5. All such results 
are shown in Appendix B, and one sagittal-coronal oblique plane and one transverse plane for each 
plan are shown in Figure 3.12 to Figure 3.15. DVHs for PTV, heart, and lungs for each of the four 
plans were computed and plotted for comparison in Figure 3.16. Dose and biologic metrics 
computed from the DVHs are compared in Table 3.5. These results likely have some dependence 
on the location of the distal PTV surface, and for CW6 the distance between the distal edge of the 
PTV and the distal side of the chest wall (Δt) was 0.4 cm on central axis. 
PTV Coverage: Dose plots (Figure 3.12 to Figure 3.15) show that the 90% isodose lines 
closely cover the distal PTV surface, or in some locations, the 80% isodose line due to the large 
variation of thickness of the PTV in the lateral direction. Most evident at the lateral edges of the 
PTV, coverage could be improved by increasing the lateral margin between the PTV and field 
edge or by a more realistic PTV (smoother edges). The PTV DVHs are similar for all plans; V47. 
5Gy values of the scanned beams are slightly less than those of the scattered beams. Maximum 
doses are less than 59 Gy (<106%). 
Effect of Scanned vs. Scattered Beams: Comparing Plan 1 (scattered, discrete energy 16.2 
MeV beam) and Plan 4 (scanned, discrete energy 15.1 MeV beam) showed that the scanned 
electron beam reduced (1) mean dose to the heart by 1.9 Gy (8.3 to 6.4 Gy) and (2) V20 Gy to the 
lung by 2.0% (19.8 to 17.8%). This resulted in reduced (1) NTCPheart by 0.2% (0.7 to 0.5%), (2) 
NTCPlungs by 0.01% (0.03 to 0.02%), and (3) SCCPlin by 2.2% (15.9 to 13.7%). 
Comparing Plan 3 (scattered, continuous energy 15.6 MeV beam) and Plan 5 (scanned, 
continuous energy 14.5 MeV beam) showed that the scanned electron beam reduced (1) mean dose 
to the heart by 2.0 Gy (7.8 to 5.8 Gy) and (2) V20Gy to the lung by 2.4% (19.1 to 16.8%). This 
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resulted in reduced (1) NTCPheart by 0.2% (0.6 to 0.4%), (2) NTCPlungs by 0.00% (0.02 to 0.02%), 
and (3) SCCPlin by 2.5% (15.3 to 12.8%). 
Effect of Continuous vs. Discrete Beam Energies: The same data above can be used to 
evaluate the benefit of continuous versus discrete energy beams. Comparing Plan 1 (scattered, 
discrete energy 16.2 MeV beam) with Plan 3 (scattered, continuous energy 15.6 MeV beam) 
showed that continuous energy beams reduced (1) mean dose to the heart by 0.5 Gy (8.3 to 7.8 
Gy) and (2) V20Gy to the lung by 0.7% (19.8 to 19.1%). This resulted in reduced (1) NTCPheart by 
0.1% (0.7 to 0.6%), (2) NTCPlungs by 0.01% (0.03 to 0.02%), and (3) SCCPlin by 0.6% (15.9% to 
15.3%). 
Comparing Plan 4 (scanned, discrete energy 15.1 MeV beam) with Plan 5 (scanned, 
continuous energy 14.5 MeV beam) showed that continuous energy beams reduced (1) mean dose 
to the heart by 0.7 Gy (6.4 to 5.8 Gy) and (2) V20Gy to the lung by 1.0% (17.8 to 16.8%). This 
resulted in reduced (1) NTCPheart by 0.09% (0.5 to 0.4%), (2) NTCPlungs by 0.00% (0.02 to 0.02%), 
and (3) SCCPlin by 0.9% (13.7 to 12.8%). 
Effect of Scanned, Continuous Energy Beams vs. Scattered, Discrete Energy Beams: The 
greatest plan improvement was comparing Plan 1 (scattered, discrete energy 16.2 MeV beam), 
current technology, with Plan 5 (scanned, continuous energy 14.5 MeV beam), possible future 
technology. This reduced (1) mean dose to the heart by 2.5 Gy (8.3 to 5.8 Gy) and (2) V20Gy to the 
lung by 3.0% (19.8 to 16.8%). This resulted in reduced (1) NTCPheart by 0.3% (0.7 to 0.4%), (2) 
NTCPlungs by 0.01% (0.03 to 0.02%), and (3) SCCPlin by 3.1% (15.9% to 12.8%). 
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Figure 3.12. Sagittal and axial images of CW6, Plan 1. CW6 (Patient Set 1) was planned using 
scattered electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique 
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane 
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Bolus is 
shaded blue, and PTV is outlined in white. Key shows dose values. 
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Figure 3.13. Sagittal and axial images of CW6, Plan 3. CW6 (Patient Set 1) was planned using 
scattered electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal, 
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in 
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique 
plane. Bolus is shaded blue, and PTV is outlined in white. Key shows dose values. 
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Figure 3.14. Sagittal and axial images of CW6, Plan 4. CW6 (Patient Set 1) was planned using 
scanned electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique 
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane 
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Bolus is 
shaded blue, and PTV is outlined in white. Key shows dose values. 
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Figure 3.15. Sagittal and axial images of CW6, Plan 5. CW6 (Patient Set 1) was planned using 
scanned electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal, 
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in 
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique 
plane. Bolus is shaded blue, and PTV is outlined in white. Key shows dose values. 
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Figure 3.16. Comparison of cumulative DVH plots for CW6 (Patient Set 1) Plans. DVH plots for 
PTV, heart, and lung are compared for Plans 1, 3, 4, and 5, as indicated in key. 
Table 3.5. Comparison of metrics for CW6 (Patient Set 1) Plans. Dose metrics are shown for PTV, 
heart, and lungs. NTCP and SCCP values are shown for heart and lungs. 
  Plan 1 Plan 3 Plan 4 Plan 5 
PTV 
D97% (Gy) 46.7 46.4 46.2 45.8 
V47.5 Gy (%) 95.0 94.5 93.5 92.7 
Max dose (Gy) 57.8 58.2 57.9 58.6 
Mean dose (Gy) 52.2 52.2 52.1 52.0 
Std Dev (Gy) 2.6 2.6 2.8 2.8 
      
Heart 
V22.5 Gy (%) 12.7 11.7 9.5 8.2 
V30 Gy (%) 6.4 5.7 4.2 3.4 
Min dose (Gy) 0.9 0.8 0.2 0.0 
Max dose (Gy) 46.2 45.8 45.6 44.3 
Mean dose (Gy) 8.3 7.8 6.4 5.8 
Std Dev (Gy) 10.3 10.0 9.4 9.0 
NTCP (%) 0.7 0.6 0.5 0.4 
      
Lungs 
V20 Gy (%) 19.8 19.1 17.8 16.8 
Min dose (Gy) 0.0 0.0 0.0 0.0 
Max dose (Gy) 50.4 50.0 49.9 49.3 
Mean dose (Gy) 9.5 9.1 8.2 7.6 
Std Dev (Gy) 13.5 13.4 13.2 12.8 
NTCP (%) 0.03 0.02 0.02 0.02 
SCCPlin (%) 15.9 15.3 13.7 12.8 
SCCPlin-exp (%) 3.0 2.8 2.3 12.8 
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3.2.2. Results for Patient Set 2 
 Plan comparisons for Patient Set 2 (CW2, CW4, CW7, and CW8) were more 
complex that those of Patient Set 1 because this study had no criteria for optimizing the location 
of the abutting edge of the lower field (greatest impact on heart dose) and upper fields (greatest 
impact on lung dose). For the scattered beams, Plan 1 placed the abutting edge as far superior as 
allowed for the minimum energy that could be used for the lower field. This likely represents the 
best plan that could be created when using scattered, discrete energy beams, which is the only plan 
deliverable with currently available radiotherapy accelerator technology. Plan 2 uses the same 
lower field as Plan 1, but assumes scattered, continuous energy beams for the upper field. Plan 3, 
which assumes scattered, continuous energy beams for both the lower and upper fields, places the 
edge at the superior aspect of the heart. The optimal location of the abutting edge is somewhere 
between that of Plans 2 and 3; however, no effort was made to determine that location in the current 
study. For such optimization, the tradeoff between heart dose and lung dose must be specified. 
Plans 4 and 5 used scanned, discrete energy beams and scanned, continuous energy beams, 
respectively with the same field placements as Plans 1 and 3, respectively. Therefore, the impact 
of scanned beams was evaluated comparing Plans 1 with Plan 4 for discrete beam energies and 
Plan 3 with Plan 5 for continuous beam energies. 
The impact of continuous energy beams was evaluated comparing Plan 1 with Plan 2 or 
Plan 3 (used scattered beams), whichever best, and Plan 4 with Plan 5 (used scanned beams). The 
latter comparison is not optimal, as abutting edges of Plan 4 and Plan 5 were different, and a Plan 
6 with the same edge location as Plan 4 might have been useful. 
As results will show, placing the abutting edge at the superior aspect of the heart (Plans 3 
and 5) resulted in higher lung doses, due to the upper field being larger than the other beam 
arrangement, and higher heart doses, apparently due to the wider penumbra of the upper, higher 
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energy field. The effect of this will be seen in the patient results to follow. Therefore, it is not 
meaningful to compare any two plans to demonstrate the benefit of using scanned, continuous 
energy beams overs scattered, discrete energy beams as was done for Patient Set 1. 
3.2.2.1. Results for Patient CW2 
Treatment planning results for CW2 (Patient Set 2) include isodose plots for three 
transverse planes and one sagittal-coronal oblique plane for Plans 1 to 5. All such results are shown 
in Appendix B, and one sagittal-coronal oblique plane and one transverse plane for each plan are 
shown in Figure 3.17 to Figure 3.21. DVHs for PTV, heart, and lungs for each of the five dose 
plans were computed and plotted for comparison in Figure 3.22. Dose and biologic metrics 
computed from these DVHs are compared in Table 3.6. These results likely have some dependence 
on the location of the distal PTV surface, and the CW2 distance between the distal edge of the 
PTV and the distal side of the chest wall (Δt) was 1.2 cm on central axis. 
PTV Coverage: Dose plots (Figure 3.17 to Figure 3.21) show that the 90% isodose lines 
closely cover the distal PTV surface, or in some locations the 80% isodose surface due to the 
jagged nature of the PTV. Most evident at the lateral edges of the PTV, coverage could be 
improved by increasing the lateral margin between the PTV and field edge or by a more realistic 
PTV (smoother edges). The PTV DVHs are similar for all plans; however, V47.5 Gy values of Plans 
3 and 5, which have the field arrangement used for the continuous energy beam (see Figure 2.3) 
are slightly greater than those of Plans 1, 2, and 4, which use a different field arrangement (see 
Figure 2.2). Although maximum doses are as large as approximately 65 Gy (117%), no significant 
volume receives more than 61 Gy (110%). 
Effect of Scanned vs. Scattered Beams: Comparing Plan 1 (scattered, discrete energy 
beams, upper 16.2 MeV and lower 13.0 MeV) and Plan 4 (scanned, discrete energy beams, upper 
15.1 MeV and lower 12.2 MeV) showed that the scanned electron beam reduced (1) mean dose to 
66 
the heart by 0.7 Gy (4.6 to 3.9 Gy) and (2) V20 Gy to the lungs by 2.5% (13.0 to 10.5%). This 
resulted in reduced (1) NTCPheart by 0.5% (0.9 to 0.40%), (2) NTCPlungs by 0.3% (1.4 to 1.0%), 
and (3) SCCPlin by 2.2% (11.0 to 8.9%). 
Comparing Plan 3 (scattered, continuous energy beams, upper 15.9 MeV and lower 13.0 
MeV) and Plan 5 (scanned, continuous energy beams, upper 14.8 MeV and lower 12.2 MeV) 
showed that the scanned electron beam reduced (1) mean dose to the heart by 2.6 Gy (8.1 to 5.5 
Gy) and (2) V20Gy to the lungs by 3.6% (22.2 to 18.6%). This resulted in reduced (1) NTCPheart by 
0.2% (0.3 to 0.1%), (2) NTCPlungs by 1.2% (3.5 to 2.3%), and (3) SCCPlin by 3.5% (18.4 to 14.9%). 
Effect of Continuous vs. Discrete Beam Energies: The same data above can be used to 
evaluate the benefit of continuous versus discrete energy beams. Comparing Plan 2 (scattered, 
continuous energy beams, upper 15.9 MeV and discrete energy lower 13.0 MeV beam) with Plan 
3 (scattered, continuous energy beams, upper 15.9 MeV and lower 13.0 MeV) showed Plan 2 to 
have lower heart and lung dose because of the beam arrangements. Therefore, Plan 2, compared 
to Plan 1 (scattered, discrete energy beams, upper 16.2 MeV and lower 13.0 MeV), shows (1) 
similar mean dose to the heart (4.6 Gy) and (2) V20 Gy to the lungs reduced slightly by 0.2% (13.0 
to 12.8%). This resulted in (1) equal NTCPheart of 0.9%, (2) NTCPlungs reduced slightly by 0.03% 
(1.4 to 1.4%), and (3) SCCPlin reduced slightly by 0.2% (11.0% to 10.8%). 
Comparing Plan 4 (scanned, discrete energy beams, upper 15.1 MeV and lower 12.2 MeV) 
with Plan 5 (scanned, continuous energy beams, upper 14.8 MeV and lower 12.2 MeV) showed 
no advantage to continuous energy. Rather, it showed the advantage of the field arrangement for 
Plan 4, as Plan 5 increased (1) mean dose to the heart by 1.6 Gy (3.9 to 5.5 Gy) and (2) V20 Gy to 
the lung by 8.2% (10.5 to 18.6%). In addition, this resulted in increased (1) NTCPheart by 0.3% 
(0.40 to 0.1%), (2) NTCPlungs by 1.3% (1.0 to 2.3%), and (3) SCCPlin by 6.0% (8.9% to 14.9%). 
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Summary: Results showed that scanned electron beams modestly reduced heart and lung 
dose and their biologic effect. NTCP changes were not likely significant because of their already 
low value for scattered beams, which was attributed to CW2 PTV requiring only 12.50.5 MeV 
(over heart) and 15.50.7 MeV (over lung) beams. Continuous energy beams showed insignificant 
improvement over discrete energy beams, because the discrete energies available were already 
near optimal. More significant was the location of the edge of abutting beams, indicating the need 
for optimizing its location in future studies. 
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Figure 3.17. Sagittal and axial images of CW2, Plan 1. CW2 (Patient Set 2) was planned using 
scattered electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique 
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane 
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Upper 
bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in white. Key 
shows dose values. 
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Figure 3.18. Sagittal and axial images of CW2, Plan 2. CW2 (Patient Set 2) was planned using 
scattered electron beams, discrete energy spacing (lower field), and continuous energy spacing 
(upper field). (a) Dose plan in the sagittal-coronal, oblique plane demarcated by the red line in 
figure (b)’s transverse plane; (b) Dose plan in transverse plane passing through central heart region, 
demarcated by red line in figure (a)’s oblique plane. Upper bolus is shaded dark blue, lower bolus 
is shaded light blue, and PTV is outlined in white. Key shows dose values. 
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Figure 3.19. Sagittal and axial images of CW2, Plan 3. CW2 (Patient Set 2) was planned using 
scattered electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal, 
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in 
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique 
plane. Upper bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in 
white. Key shows dose values. 
 
71 
 
Figure 3.20. Sagittal and axial images of CW2, Plan 4. CW2 (Patient Set 2) was planned using 
scanned electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique 
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane 
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Upper 
bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in white. Key 
shows dose values. 
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Figure 3.21. Sagittal and axial images of CW2, Plan 5. CW2 (Patient Set 2) was planned using 
scanned electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal, 
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in 
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique 
plane. Bolus is shaded blue, and PTV is outlined in white. Key shows dose values. 
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Figure 3.22. Comparison of cumulative DVH plots for CW2 (Patient Set 2) Plans. DVH plots for 
PTV, heart, and lung are compared for Plans 1, 2, 3, 4, and 5, as indicated in key. 
Table 3.6. Comparison of metrics for CW2 (Patient Set 2) Plans. Dose metrics are shown for PTV, 
heart, and lungs. NTCP and SCCP values are shown for heart and lungs. 
  Plan 1 Plan 2 Plan 3 Plan 4 Plan 5 
PTV 
D97% (Gy) 46.9 46.9 48.2 46.3 47.4 
V47.5 Gy (%) 96.3 96.3 98.4 96.0 97.6 
Max dose (Gy) 64.5 64.2 67.1 63.0 66.4 
Mean dose (Gy) 54.0 54.0 54.6 54.0 54.4 
Std Dev (Gy) 3.1 3.1 2.9 3.1 2.9 
       
Heart 
V22.5 Gy (%) 3.1 3.1 8.4 1.7 4.6 
V30 Gy (%) 0.4 0.4 2.8 0.1 0.8 
Min dose (Gy) 0.7 0.7 2.0 0.1 0.7 
Max dose (Gy) 38.0 38.0 43.4 36.1 39.2 
Mean dose (Gy) 4.6 4.6 8.1 3.9 5.5 
Std Dev (Gy) 5.8 5.8 8.0 4.9 6.9 
NTCP (%) 0.9 0.9 0.3 0.4 0.1 
      
Lungs 
V20 Gy (%) 13.0 12.8 22.2 10.5 18.6 
Min dose (Gy) 0.0 0.0 0.0 0.0 0.0 
Max dose (Gy) 47.8 47.7 50.9 46.5 50.2 
Mean dose (Gy) 6.6 6.5 10.9 5.3 8.8 
Std Dev (Gy) 10.1 10.1 13.3 9.2 12.6 
NTCP (%) 1.4 1.4 3.5 1.0 2.3 
SCCPlin (%) 11.0 10.8 18.4 8.9 14.9 
SCCPlin-exp (%) 2.9 2.8 3.8 2.3 3.0 
74 
3.2.2.2. Results for Patient CW4 
Treatment planning results for CW4 (Patient Set 2) include isodose plots for three 
transverse planes and one sagittal-coronal oblique plane for Plans 1 to 5. However, Plans 1 and 2 
are identical as the optimal, continuous energy for the upper field was the same as the discrete 
energy used in Plan 1. All such results are shown in Appendix B, and one sagittal-coronal oblique 
plane and one transverse plane for each plan are shown Figure 3.23 to Figure 3.26. DVHs for PTV, 
heart, and lungs for each of the five dose plans were computed and plotted for comparison in Figure 
3.27. Dose and biologic metrics computed from these DVHs are compared in Table 3.7. These 
results likely have some dependence on the location of the distal PTV surface, and the CW4 
distance between the distal edge of the PTV and the distal side of the chest wall (Δt) was 1.9 cm 
on central axis. 
PTV Coverage: Dose plots (Figure 3.23 to Figure 3.26) show that the 90% isodose lines 
closely cover the distal PTV surface, or in some locations the 80% isodose surface due to the 
jagged nature of the PTV. Most evident at the lateral edges of the PTV, coverage could be 
improved by increasing the lateral margin between the PTV and field edge or by a more realistic 
PTV (smoother edges). The PTV DVHs are similar for all plans; however, V47.5 Gy values of Plans 
1 and 2 (≈95%), which use scattered beams are greater than those for Plans 3 and 5 (≈91%). This 
is possibly due to the different dose distributions given by the scanned and scattered beams, as 
well as the different field arrangements. Although maximum doses are as large as approximately 
66 Gy (119%), no significant volume receives more than 59 Gy (105%). 
Effect of Scanned vs. Scattered Beams: Comparing Plan 1 (scattered, discrete energy 
beams, upper 21.3 MeV and lower 16.2 MeV) and Plan 4 (scanned, discrete energy beams, upper 
18.4 MeV and lower 15.1 MeV) showed that the scanned electron beam reduced (1) mean dose to 
the heart by 1.4 Gy (3.8 to 2.4 Gy) and (2) V20 Gy to the lungs by 2.5% (11.8 to 9.2%). This 
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resulted in insignificant reduction to (1) NTCPheart by 0.01% (0.01 to 0.00%) and (2) NTCPlungs by 
0.00% (0.01 to 0.01%), because of their already low values, and reduction to (3) SCCPlin by 2.8% 
(10.9 to 8.1%). 
Comparing Plan 3 (scattered, continuous energy beams, upper 21.3 MeV and lower 16.2 
MeV) and Plan 5 (scanned, continuous energy beams, upper 18.4 MeV and lower 15.1 MeV) 
showed that the scanned electron beam reduced (1) mean dose to the heart by 1.2 Gy (3.6 to 2.4 
Gy) and (2) V20Gy to the lung by 1.6% (11.7 to 10.1%). This resulted in insignificant reduction to 
(1) NTCPheart by 0.01% (0.01 to 0.00%) and (2) NTCPlungs by 0.00% (0.01 to 0.01%), because of 
their already low values, and reduction to (3) SCCPlin by 1.9% (10.7 to 8.8%). 
Effect of Continuous vs. Discrete Beam Energies: For Plan 2, the optimal continuous 
energy for the upper beam was identical to the discrete energy used in Plan 1. Thus, Plan 1 and 
Plan 2 are identical. The optimal continuous energy for all beams in Plans 2, 3, and 5 were the 
same as the discrete energies for the beams in Plans 1 and 4. Thus, no conclusions can be drawn 
about the effect of using continuous vs. discrete energy spacing for this patient, CW4. 
Impact of Location of Edges of Abutting Beams: Comparing Plan 2 (scattered, continuous 
energy beams, upper 21.3 MeV and discrete energy lower 16.2 MeV beam) with Plan 3 (scattered, 
continuous energy beams, upper 21.3 MeV and lower 16.2 MeV) showed Plan 2 to have essentially 
identical heart and lung dose due to the boundaries given to the upper and lower PTVs, but slightly 
lower SCCPlin. Therefore, Plan 3, compared to Plan 1 (scattered, discrete energy beams, upper 21.3 
MeV and lower 16.2 MeV), shows small reduced (1) mean dose to the heart by 0.2 Gy (3.8 to 3.6 
Gy) and (2) V20 Gy to the lung reduced slightly by 0.08% (11.8 to 11.7%). This resulted in (1) equal 
NTCPheart of 0.01%, (2) equal NTCPlungs 0.01%, and (3) SCCPlin reduced slightly by 0.2% (10.9% 
76 
to 10.7%). These differences are due to the location of the edge of abutting beams, as the energies 
used for each comparison are identical. 
Comparing Plan 4 (scanned, discrete energy beams, upper 18.4 MeV and lower 15.1 MeV) 
with Plan 5 (scanned, continuous energy beams, upper 18.4 MeV and lower 15.1 MeV) showed 
no advantage to continuous energy; none would be expected since the selected discrete energies 
were the same as continuous ones. Rather, it showed the advantage of the field arrangement 
(abutment location) for Plan 4, as Plan 5 (1) had equal mean dose to the heart (2.4 Gy), but (2) 
increased V20 Gy to the lung by 0.9% (9.2 to 10.1%). This resulted in (1) identical NTCPheart of 
0.00%, (2) identical NTCPlungs of 0.01%, and (3) increased SCCPlin by 0.7% (8.1% to 8.8%). 
Summary: Results showed that scanned electron beams slightly reduced heart and lung 
dose and their biologic effect. NTCP changes were not likely significant because of their already 
low value for scattered beams, which was attributed to the larger separation (1.9 cm) between the 
PTV and distal chest wall. Improvement of continuous energy beams over discrete energy beams 
was unable to be evaluated for CW4. Also, the location of the edge of abutting beams had little 
effect, due to the already low normal tissue doses and biologic effects. This is likely due to the 
larger separation between the distal PTV surface and the distal chest wall on central axis. 
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Figure 3.23. Sagittal and axial images of CW4, identical Plans 1 and 2. CW4 (Patient Set 2) was 
planned using scattered electron beams and discrete energy spacing for Plan 1 and scattered beams 
with discrete energy spacing (lower field) and continuous energy spacing (upper field) for Plan 2. 
(a) Dose plan in the sagittal-coronal, oblique plane demarcated by the red line in figure (b)’s 
transverse plane; (b) Dose plan in transverse plane passing through central heart region, 
demarcated by red line in figure (a)’s oblique plane. Upper bolus is shaded dark blue, lower bolus 
is shaded light blue, and PTV is outlined in white. Key shows dose values. 
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Figure 3.24. Sagittal and axial images of CW4, Plan 3. CW4 (Patient Set 2) was planned using 
scattered electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal, 
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in 
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique 
plane. Upper bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in 
white. Key shows dose values. 
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Figure 3.25. Sagittal and axial images of CW4, Plan 4. CW4 (Patient Set 2) was planned using 
scanned electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique 
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane 
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Upper 
bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in white. Key 
shows dose values. 
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Figure 3.26. Sagittal and axial images of CW4, Plan 5. CW4 (Patient Set 2) was planned using 
scanned electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal, 
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in 
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique 
plane. Upper bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in 
white. Key shows dose values. 
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Figure 3.27. Comparison of cumulative DVH plots for CW4 (Patient Set 2) Plans. DVH plots for 
PTV, heart, and lung are compared for Plans 1, 2, 3, 4, and 5, as indicated in key. Note that Plans 
1 and 2 are identical for CW4. 
Table 3.7. Comparison of metrics for CW4 (Patient Set 2) Plans. Dose metrics are shown for PTV, 
heart, and lungs. NTCP and SCCP values are shown for heart and lungs. Note that Plans 1 and 2 
are identical for CW4. 
  Plan 1 Plan 2 Plan 3 Plan 4 Plan 5 
PTV 
D97% (Gy) 45.7 45.7 44.3 43.2 43.5 
V47.5 Gy (%) 94.75 94.75 91.63 91.87 91.02 
Max dose (Gy) 63.06 63.06 66.55 65.98 64.79 
Mean dose (Gy) 53.83 53.83 53.50 53.48 53.48 
Std Dev (Gy) 0.24 0.24 0.34 0.04 0.4 
       
Heart 
V22.5 Gy (%) 0.4 0.4 0.6 0.1 0.1 
V30 Gy (%) 0.0 0.0 0.0 0.1 0.2 
Min dose (Gy) 1.2 1.2 0.6 0.5 0.1 
Max dose (Gy) 32.7 32.7 33.3 27.9 28.6 
Mean dose (Gy) 3.8 3.8 3.6 2.4 2.4 
Std Dev (Gy) 3.6 3.6 3.9 3.2 3.3 
NTCP (%) 0.01 0.01 0.01 0.0 0.0 
      
Lungs 
V20 Gy (%) 11.8 11.8 11.7 9.2 10.1 
Min dose (Gy) 0.0 0.0 0.0 0.0 0.0 
Max dose (Gy) 48.1 48.1 48.8 46.1 50.4 
Mean dose (Gy) 6.5 6.5 6.4 4.8 5.2 
Std Dev (Gy) 9.6 9.6 9.8 8.7 9.5 
NTCP (%) 0.01 0.01 0.01 0.01 0.01 
SCCPlin (%) 10.9 10.9 10.7 8.1 8.8 
SCCPlin-exp (%) 3.2 3.2 3.1 2.3 2.3 
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3.2.2.3. Results for Patient CW7 
Treatment planning results for CW7 (Patient Set 2) include isodose plots for three 
transverse planes and one sagittal-coronal oblique plane for Plans 1 to 5. However, Plans 1 and 2 
are identical as the optimal, continuous energy for the upper field was the same as the discrete 
energy used in Plan 1. All such results are shown in Appendix B, and one sagittal-coronal oblique 
plane and one transverse plane for each plan are shown in Figure 3.28 to Figure 3.31. DVHs for 
PTV, heart, and lungs for each of the five dose plans were computed and plotted for comparison 
in Figure 3.32. Dose and biologic metrics computed from these DVHs are compared in Table 3.8. 
These results likely have some dependence on the location of the distal PTV surface, and the CW7 
distance between the distal edge of the PTV and the distal side of the chest wall (Δt) was 0.9 cm 
on central axis. 
PTV Coverage: Dose plots (Figure 3.28 to Figure 3.31) show that the 90% isodose lines 
closely cover the distal PTV surface, or in some locations the 80% isodose surface due to the 
jagged nature of the PTV. Most evident at the lateral edges of the PTV, coverage could be 
improved by increasing the lateral margin between the PTV and field edge or by a more realistic 
PTV (smoother edges). The PTV DVHs are similar for all plans; V47.5 Gy values of Plans 3 and 5, 
which have the field arrangement used for the continuous energy beams (see Figure 2.3) are 
slightly greater than those of Plans 1, 2, and 4, which use a different field arrangement (see Figure 
2.2). Although maximum doses are as large as approximately 69 Gy (124%), no significant volume 
receives more than 62 Gy (112%). 
Effect of Scanned vs. Scattered Beams: Comparing Plan 1 (scattered, discrete energy 
beams, upper 21.3 MeV and lower 16.2 MeV) and Plan 4 (scanned, discrete energy beams, upper 
18.4 MeV and lower 15.1 MeV) showed that the scanned electron beam reduced (1) mean dose to 
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the heart by 2.6 Gy (9.6 to 7.0 Gy) and (2) V20 Gy to the lungs by 4.1% (20.6 to 16.5%). This 
resulted in reduced (1) NTCPheart by 0.2% (0.5 to 0.3%), (2) NTCPlungs by 0.02% (0.04 to 0.02%), 
and (3) SCCPlin by 4.6% (18.2 to 13.7%). 
Comparing Plan 3 (scattered, continuous energy beams, upper 21.3 MeV and lower 16.2 
MeV) and Plan 5 (scanned, continuous energy beams, upper 18.4 MeV and lower 15.1 MeV) 
showed that the scanned electron beam reduced (1) mean dose to the heart by 2.2 Gy (9.7 to 7.5 
Gy) and (2) V20 Gy to the lungs by 1.2% (17.7 to 16.5%). This resulted in reduced (1) NTCPheart by 
0.2% (0.6 to 0.4%), (2) NTCPlungs by 0.01% (0.03 to 0.02), and (3) SCCPlin by 1.8% (15.9 to 
14.1%). 
Effect of Continuous vs. Discrete Beam Energies: For Plan 2, the optimal continuous 
energy for the upper beam was identical to the discrete energy used in Plan 1. Thus, Plan 1 and 
Plan 2 are identical. The optimal continuous energy for all beams in Plans 2,3, and 5 were the same 
as the discrete energies for the beams in Plans 1 and 4. Thus, no conclusions can be drawn about 
the effect of using continuous vs. discrete energy spacing for this patient, CW7. 
Impact of Location of Edges of Abutting Beams: Comparing Plan 2 (scattered, continuous 
energy beams, upper 21.3 MeV and discrete energy lower 16.2 MeV beam) with Plan 3 (scattered, 
continuous energy beams, upper 21.3 MeV and lower 16.2 MeV) showed (1) mean dose to the 
heart by 0.0 Gy (9.7 to 9.7 Gy) and (2) V20 Gy to the lungs by 2.9% (20.6 to 17.7%). This resulted 
in a marginally increased (1) NTCPheart by 0.06% (0.5 to 0.6%) and decreased (2) NTCPlungs by 
0.01% (0.04 to 0.03%), and (3) SCCPlin by 2.3% (18.2 to 15.9%). These differences are due to the 
location of the edge of abutting beams, as the energies used for each comparison are identical. 
Comparing Plan 4 (scanned, discrete energy beams, upper 18.4 MeV and lower 15.1 MeV) 
with Plan 5 (scanned, continuous energy beams, upper 14.5 MeV and lower 10.5 MeV) showed 
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no advantage to continuous energy. Rather, it showed the advantage of the field arrangement for 
Plan 4, as Plan 5 increased (1) mean dose to the heart by 0.5 Gy (7.0 to 7.5 Gy) why the V20 Gy to 
the lung remained constant at 16.5%. This resulted in increased (1) NTCPheart of 0.06% (0.3 to 
0.4%), identical NTCPlungs values of 0.02%, and increased SCCPlin by 0.4% (13.7% to 14.1%). 
Effect of Scanned, Continuous Beam Energies vs. Scattered, Discrete Beam Energies: This 
comparison was overshadowed by the abutting border of Plan 5 being 0.25 cm inferior to that of 
Plan 1. Plan 4 metrics were better than those of Plan 5, negating this comparison. 
Summary: Results showed that scanned electron beams modestly reduced heart and lung 
dose and their biologic effects. Continuous energy beams showed insignificant improvement over 
discrete energy beams, because the discrete energies available were already optimal. More 
significant was the location of the edge of abutting beams, indicating the need for optimizing its 
location in future studies. 
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Figure 3.28. Sagittal and axial images of CW7, Plans 1 and 2. CW7 (Patient Set 2) was planned 
using scattered electron beams and discrete energy spacing for Plan 1 and scattered beams with 
discrete energy spacing (lower field) and continuous energy spacing (upper field). Because the 
discrete energy is the optimal energy for the upper field, Plans 1 and 2 are identical (a) Dose plan 
in the sagittal-coronal, oblique plane demarcated by the red line in figure (b)’s transverse plane; 
(b) Dose plan in transverse plane passing through central heart region, demarcated by red line in 
figure (a)’s oblique plane. Upper bolus is shaded dark blue, lower bolus is shaded light blue, and 
PTV is outlined in white. Key shows dose values. 
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Figure 3.29. Sagittal and axial images of CW7, Plan 3. CW7 (Patient Set 2) was planned using 
scattered electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal, 
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in 
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique 
plane. Upper bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in 
white. Key shows dose values. 
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Figure 3.30. Sagittal and axial images of CW7, Plan 4. CW7 (Patient Set 2) was planned using 
scanned electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique 
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane 
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Upper 
bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in white. Key 
shows dose values. 
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Figure 3.31. Sagittal and axial images of CW7, Plan 5. CW7 (Patient Set 2) was planned using 
scanned electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal, 
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in 
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique 
plane. Bolus is shaded blue, and PTV is outlined in white. Key shows dose values. 
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Figure 3.32. Comparison of cumulative DVH plots for CW7 (Patient Set 2) Plans. DVH plots for 
PTV, heart, and lung are compared for Plans 1, 2, 3, 4, and 5, as indicated in key 
Table 3.8. Comparison of metrics for CW7 (Patient Set 2) Plans. Dose metrics are shown for PTV, 
heart, and lungs. NTCP and SCCP values are shown for heart and lungs. 
  Plan 1 Plan 2 Plan 3 Plan 4 Plan 5 
PTV 
D97% (Gy) 46.9 46.9 46.4 46.0 45.6 
V47.5 Gy (%) 96.4 96.4 96.3 96.2 95.6 
Max dose (Gy) 69.6 69.6 68.4 68.4 68.3 
Mean dose (Gy) 54.2 54.2 54.1 54.0 54.0 
Std Dev (Gy) 3.2 3.2 3.2 3.2 3.3 
       
Heart 
V22.5 Gy (%) 11.6 11.6 12.8 8.0 9.2 
V30 Gy (%) 4.8 4.8 5.7 2.6 3.3 
Min dose (Gy) 1.9 1.9 1.8 0.7 0.8 
Max dose (Gy) 46.9 46.9 46.3 44.3 44.3 
Mean dose (Gy) 9.6 9.6 9.7 7.0 7.5 
Std Dev (Gy) 9.0 9.0 9.4 8.3 8.7 
NTCP (%) 0.5 0.5 0.6 0.3 0.4 
      
Lungs 
V20 Gy (%) 20.6 20.6 17.7 16.5 16.5 
Min dose (Gy) 0.9 0.9 0.4 0.2 0.2 
Max dose (Gy) 99.4 99.4 97.7 95.7 97.5 
Mean dose (Gy) 19.5 19.5 17.0 14.6 15.1 
Std Dev (Gy) 24.3 24.3 23.1 22.3 23.1 
NTCP (%) 0.04 0.04 0.03 0.02 0.02 
SCCPlin (%) 18.2 18.2 15.9 13.7 14.1 
SCCPlin-exp (%) 4.0 4.0 3.7 3.0 3.0 
90 
3.2.2.4. Results for Patient CW8 
Treatment planning results for CW8 (Patient Set 2) include isodose plots for three 
transverse planes and one sagittal-coronal oblique plane for Plans 1 to 5. All such results are shown 
in Appendix B, and one sagittal-coronal oblique plane and one transverse plane for each plan are 
shown in Figure 3.33 to Figure 3.37. DVHs for PTV, heart, and lungs for each of the five dose 
plans were computed and plotted for comparison in Figure 3.38. Dose and biologic metrics 
computed from these DVHs are compared in Table 3.9. These results likely have some dependence 
on the location of the distal PTV surface, and the CW8 distance between the distal edge of the 
PTV and the distal side of the chest wall (Δt) was 0.6 cm on central axis. 
PTV Coverage: Dose plots (Figure 3.33 to Figure 3.37) show that the 90% isodose lines 
closely cover the distal PTV surface, or in some locations the 80% isodose surface due to the 
jagged nature of the PTV. Most evident at the lateral edges of the PTV, coverage could be 
improved by increasing the lateral margin between the PTV and field edge or by a more realistic 
PTV (smoother edges). The PTV DVHs are similar for all plans; V47.5 Gy values of Plans 3 and 5, 
which have the field arrangement used for the continuous energy beams (see Figure 2.3) are 
slightly greater than those of Plans 1, 2, and 4, which use a different field arrangement (see Figure 
2.2). Although maximum doses are as large as approximately 60 Gy (108%), no significant volume 
receives more than 58 Gy (105%). 
Effect of Scanned vs. Scattered Beams: Comparing Plan 1 (scattered, discrete energy 
beams, upper 16.2 MeV and lower 13.0 MeV) and Plan 4 (scanned, discrete energy beams, upper 
14.5 MeV and lower 12.2 MeV) showed that the scanned electron beam reduced (1) mean dose to 
the heart by 0.6 Gy (4.3 to 3.7 Gy) and (2) V20 Gy to the lungs by 2.9% (17.7 to 14.8%). This 
resulted in reduced (1) NTCPheart by 0.06% (0.1 to 0.06%), (2) NTCPlungs by 0.01% (0.02 to 
0.01%), and (3) SCCPlin by 2.3% (13.1 to 10.8%). 
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Comparing Plan 3 (scattered, continuous energy beams, upper 15.6 MeV and lower 11.1 
MeV) and Plan 5 (scanned, continuous energy beams, upper 14.5 MeV and lower 10.5 MeV) 
showed that the scanned electron beam reduced (1) mean dose to the heart by 0.9 Gy (3.9 to 3.0 
Gy) and (2) V20 Gy to the lungs by 3.2% (16.4 to 13.1%). This resulted in reduced (1) NTCPheart by 
0.06% (0.1 to 0.06%), (2) NTCPlungs by 0.01% (0.02 to 0.01%), and (3) SCCPlin by 2.5% (12.2 to 
9.7%). 
Effect of Continuous vs. Discrete Beam Energies: The same data above can be used to 
evaluate the benefit of continuous versus discrete energy beams. Comparing Plan 2 (scattered, 
continuous energy beams, upper 15.6 MeV and discrete energy lower 13.0 MeV beam) with Plan 
1 (scattered, discrete energy beams, upper 16.2 MeV and lower 13.0 MeV), there is insignificant 
differences in PTV and heart metrics, as the only difference in plans was a 0.6 MeV lower energy 
in the upper field. There were small changes in the lung metrics as Plan 2 showed reduced V20 Gy 
to the lungs by 0.3% (17.7 to 17.4%) and (2) SCCPlin by 0.3% (13.1 to 12.9%). 
Comparing Plan 2 (scattered, continuous energy beams, upper 15.6 MeV and discrete 
energy lower 13.0 MeV beam) with Plan 3 (scattered, continuous energy beams, upper 15.6 MeV 
and lower 13.0 MeV), differing only by the inferior border of the upper field being 0.75 cm 
inferior, showed reduced (1) mean dose to the heart by 0.3 Gy (4.2 to 3.9 Gy) and (2) V20Gy to the 
lungs by 1.0% (17.4 to 16.4%). This resulted in reduced (1) NTCPheart by 0.00% (0.1 to 0.1%), (2) 
NTCPlungs by 0.00% (0.02 to 0.02%), and (3) SCCPlin by 0.7% (12.9 to 12.2%). 
Comparing Plan 4 (scanned, discrete energy beams, upper 14.5 MeV and lower 12.2 MeV) 
with Plan 5 (scanned, continuous energy beams, upper 14.5 MeV and lower 10.5 MeV) showed 
decreased (1) mean dose to the heart by 0.6 Gy (3.7 to 3.0 Gy) and (2) V20Gy to the lung by 1.6% 
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(14.8 to 13.1%). This resulted in identical NTCPheart values of 0.06% and NTCPlungs vales of 
0.01%, and decreased SCCPlin by 1.2% (10.8% to 9.7%). 
Effect of Scanned, Continuous Beam Energies vs. Scattered, Discrete Beam Energies: 
Even though the abutting border of the upper and lower fields differed, there was still benefit. 
Comparing Plan 5 (scanned, continuous energy beams, upper 14.5 MeV and lower 10.5 MeV) 
with Plan 1 (scattered, discrete energy beams, upper 16.2 MeV and lower 13.0 MeV) showed that 
scanned, continuous energy beams reduced (1) mean dose to the heart by 1.3 Gy (4.3 to 3.0 Gy) 
and (2) V20Gy to the lung by 4.6% (17.7 to 13.1%). This resulted in reduced (1) NTCPheart by 0.0% 
(0.1 to 0.1%), (2) NTCPlungs by 0.0% (0.0 to 0.0%), and (3) SCCPlin by 3.4% (13.1% to 9.7%). 
Summary: Results showed that scanned electron beams modestly reduced heart and lung 
dose and their biologic effect. NTCP changes were not likely significant because of their already 
low value for scattered beams. Continuous energy beams showed insignificant improvement over 
discrete energy beams, because the discrete energies available were already near optimal. More 
significant was the location of the edge of abutting beams, indicating the need for optimizing its 
location in future studies. 
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Figure 3.33. Sagittal and axial images of CW8, Plan 1. CW8 (Patient Set 2) was planned using 
scattered electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique 
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane 
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Upper 
bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in white. Key 
shows dose values. 
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Figure 3.34. Sagittal and axial images of CW8, Plan 2. CW8 (Patient Set 2) was planned using 
scattered electron beams, discrete energy spacing (lower field), and continuous energy spacing 
(upper field). (a) Dose plan in the sagittal-coronal, oblique plane demarcated by the red line in 
figure (b)’s transverse plane; (b) Dose plan in transverse plane passing through central heart region, 
demarcated by red line in figure (a)’s oblique plane. Upper bolus is shaded dark blue, lower bolus 
is shaded light blue, and PTV is outlined in white. Key shows dose values. 
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Figure 3.35. Sagittal and axial images of CW8, Plan 3. CW8 (Patient Set 2) was planned using 
scattered electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal, 
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in 
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique 
plane. Upper bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in 
white. Key shows dose values. 
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Figure 3.36. Sagittal and axial images of CW8, Plan 4. CW8 (Patient Set 2) was planned using 
scanned electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique 
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane 
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Upper 
bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in white. Key 
shows dose values. 
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Figure 3.37. Sagittal and axial images of CW8, Plan 5. CW8 (Patient Set 2) was planned using 
scanned electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal, 
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in 
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique 
plane. Upper bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in 
white. Key shows dose values. 
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Figure 3.38. Comparison of cumulative DVH plots for CW8 (Patient Set 2) Plans. DVH plots for 
PTV, heart, and lung are compared for Plans 1, 2, 3, 4, and 5, as indicated in key 
Table 3.9. Comparison of metrics for CW8 (Patient Set 2) Plans. Dose metrics are shown for PTV, 
heart, and lungs. NTCP and SCCP values are shown for heart and lungs. 
  Plan 1 Plan 2 Plan 3 Plan 4 Plan 5 
PTV 
D97% (Gy) 44.7 44.7 43.9 43.9 42.9 
V47.5 Gy (%) 92.5 92.5 93.7 91.6 91.5 
Max dose (Gy) 58.4 58.4 60.0 58.4 59.1 
Mean dose (Gy) 52.2 52.2 52.5 52.1 52.2 
Std Dev (Gy) 3.1 3.0 3.1 3.2 3.3 
       
Heart 
V22.5 Gy (%) 3.4 3.4 3.3 2.0 1.8 
V30 Gy (%) 0.7 0.7 0.8 0.3 0.3 
Min dose (Gy) 0.5 0.5 0.0 0.0 0.0 
Max dose (Gy) 44.1 44.1 44.7 43.0 43.4 
Mean dose (Gy) 4.3 4.2 3.9 3.7 3.0 
Std Dev (Gy) 6.3 6.3 6.2 5.2 5.1 
NTCP (%) 0.1 0.1 0.1 0.1 0.1 
      
Lungs 
V20 Gy (%) 17.7 17.4 16.4 14.8 13.1 
Min dose (Gy) 0.0 0.0 0.0 0.0 0.0 
Max dose (Gy) 48.0 46.7 48.7 45.7 48.0 
Mean dose (Gy) 7.8 7.7 7.2 6.5 5.8 
Std Dev (Gy) 12.1 12.0 11.9 11.1 10.5 
NTCP (%) 0.0 0.0 0.0 0.0 0.0 
SCCPLin (%) 13.1 12.9 12.2 10.8 9.7 
SCCPLin-Exp (%) 2.5 2.4 2.3 2.1 1.9 
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Chapter 4. Discussion of Results 
The purpose of this study was to determine the potential impact of availability of discrete 
versus continuous beam energies and of beams flattened using scanned beam technology versus 
dual scattering foils on the treatment of post-mastectomy breast cancer patients. The quality of 
post-mastectomy radiotherapy treatment plans was evaluated by examining PTV coverage (chest 
wall, excluding supraclavicular field), heart dose, and lung dose for left sided postmastectomy 
patients. Both dose and biologic metrics were calculated for comparison of multiple plans for each 
patient. In addition to the treatment modality dependences, the results of this study also showed 
some dependence on beam energy, i.e. R90, (related to maximum thickness of PTV), distance of 
tissue between distal PTV surface and distal chest wall surface (onset of lungs or heart), and 
number of electron fields used to treat PTV (one versus two, the upper field of the latter having a 
feathered edge). Below the impact of electron beam technology as well as patient and beam 
parameters on dose and biologic metrics are discussed. 
4.1. Impact on Heart Dose 
For all IM-BECT treatment plans, dose to the heart was low due to using electron beams 
with conformal bolus, as previously reported.21 For the seven patients studied, the maximum values 
for V22.5Gy. V30Gy, and Dmean were 12.7%, 6.4%, and 9.6 Gy for Plan 1, which is the only plan 
currently deliverable using clinically available technology (scattered, discrete energy beams). 
These plans produced a maximum value for NTCP of 0.9%. 
Effects of using scattered versus scanned beams were best assessed by comparing Plan 1 
with Plan 4 and Plan 3 with Plan 5 for Patient Set 1, because they required only a single beam; 
however, comparisons for Patient Set 2 were also meaningful, even though Plan 5 did not have the 
optimal location of the abutment edge for the lower and upper fields. Plots of V22.5Gy. V30Gy, 
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and Dmean (scattered beam value less scanned beam value) versus R90 showed the general trend 
that these metrics increased as R90 increased (see Figure 4.1). As expected, scanned beams showed 
the greatest effect (benefit) at the higher energies (Rp  5 cm). For the seven patients studied, 
maximum V22.5Gy. V30Gy, and Dmean values for Plan 4, which could be deliverable by scanned, 
discrete energy beams, were reduced to 9.5%, 4.2%, and 7.0 Gy. 
 
Figure 4.1. Reduction in heart dose metrics (scattered beam value less scanned beam value) versus 
the average R90 of discrete and continuous energy beams overlying heart. The values shown are 
the average of the differences in dose metrics between Plan 1 and Plan 4 and between Plan 3 and 
Plan 5 (scattered beam value less scanned beam value). These plots illustrate the effect different 
R90 values have on heart metrics. The general trend is that between scattered and scanned beams, 
as the R90 increases, so do ΔV22.5Gy. ΔV30Gy, and ΔDmean. The CW patient number is indicated 
inside the circles for Patient Set 1 (1,3,6) and squares for Patient Set 2 (2,4,7,8). 
Effects of using continuous versus discrete energy beams were best assessed by comparing 
Plan 1 with Plan 3 and Plan 4 with Plan 5 for Patient Set 1. Comparisons for Patient Set 2 were 
not particularly informative because the location of the edge of abutting the upper and lower fields 
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was not optimized. Plots of V22.5Gy. V30Gy, and Dmean (discrete energy beam value less 
continuous energy beam value) versus R90 suggested the general trend that these metrics increased 
as R90 increased (see Figure 4.2). Although only data for three patients, all showed improvement 
with that for the highest energy beam (R90 = 6 cm) being the greatest; for Patient 1 V22.5Gy, V30Gy, 
and Dmean values were reduced by 5.6 %, 2.2%, and 1.9 Gy, respectively. Appreciate that this effect 
could be negligible if the discrete energy selected were the optimal energy; however, in some cases 
both effects (large R90 and suboptimal energy) can be considerable. 
 
Figure 4.2. Reduction in heart dose metrics (discrete energy beam value less continuous energy 
beam value) versus the average R90 of discrete and continuous energy beams overlying heart. The 
values shown are the average of the differences in dose metrics between Plan 1 and Plan 3 and 
between Plan 4 and Plan 5 (discrete beam value less continuous beam value) for patients in Patient 
Set 1. These plots illustrate the effect different R90 values have on heart metrics. The general trend 
is that between discrete and continuous beams as the R90 increases, so do ΔV22.5Gy. ΔV30Gy, and 
ΔDmean. The CW patient number (1,3,6) is indicated inside the circles. 
Combining these effects, scanned, continuous energy beams can provide treatment plans 
significantly superior to scattered, discrete energy beams. This is best illustrated by CW1, whose 
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metrics for Plan 1 versus Plan 5 were reduced, V22.5Gy from 10.4% to 2.2%, V30Gy from 3.1% to 
0.1%, Dmean from 8.3 Gy to 4.3 Gy, and NTCP from 0.4% to 0.1%. 
Dose to the heart also depended on (1) the thickness of tissue (t) between the distal edge 
of the PTV and the heart and (2) the energy (hence R90) required for PTV coverage. The former is 
illustrated by comparing V22.5Gy. V30Gy, and Dmean versus t for Plan 1 (scattered, discrete energy 
beams) for each of the seven patients planned in this study (see Figure 4.3), which showed the 
trend that the smaller the value of t, the greater the heart dose. The latter is confirmed by 
comparing V22.5Gy. V30Gy, and Dmean versus R90 for Plan 1 (scattered, discrete energy beams) for 
each of the seven patients planned in this study ( see Figure 4.4), which showed the trend that the 
greater the energy (hence R90), the greater the heart dose. Therefore, patient plans with the smaller 
t and the greater R90 are those that possibly could benefit most from availability of scanned and/or 
continuous energy beams. 
 
Figure 4.3. Effect of Δt on heart metrics. These plots illustrate the effect of Δt values on heart 
metrics for Plan 1. The general trend is that as Δt increases, V22.5Gy. V30Gy, and Dmean decrease. The 
CW patient number is indicated inside the circles for Patient Set 1 (1,3,6) and squares for Patient 
Set 2 (2,4,7,8). 
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Figure 4.4. Effect of R90 on heart metrics. These plots illustrate the effect of R90 values on heart 
metrics for Plan 1. The general trend is that as R90 increases, so do V22.5Gy. V30Gy, and Dmean. The 
patient number is indicated inside the circles for Patient Set 1 (1,3,6) and squares for Patient Set 2 
(2,4,7,8). 
4.2. Impact on Lung Dose 
For all IM-BECT treatment plans, dose to the lung was low due to using electron beams 
with conformal bolus, as previously reported.21 For the seven patients studied, V20Gy values ranged 
from 11.8% to 20.6% for Plan 1, the only plan deliverable using current scattered, discrete energy 
beams. These doses are acceptably low, with NTCP values ranging from 0.01% to 1.4%. However, 
SCCPlin values, which ranged from 10.9% to 18.6%, might be of greater clinical significance. 
Effects of using scattered versus scanned beams were best assessed by comparing Plan 1 
with Plan 4 and Plan 3 with Plan 5 for Patient Set 1, because they required only a single beam; 
however, comparisons for Patient Set 2 were also meaningful, even though Plan 5 did not have the 
ideal location of the abutment edge for the lower and upper fields. Plots of V20Gy and SCCPlin 
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(scattered beam value less scanned beam value) versus R90 showed the general trend that these 
differences increased as R90 increased (see Figure 4.5). In other words, as expected, scanned beams 
showed greater benefit at the higher energies (Rp  5 cm). For the seven patients studied, V20Gy 
values were reduced to range from 9.2% to 17.8% and SCCPlin values were reduced to range from 
8.1% to 13.7% for Plan 4, which could be deliverable by scanned, discrete energy beams. 
 
Figure 4.5. Reduction in lung dose metrics (scattered beam value less scanned beam value) versus 
the average R90 of discrete and continuous energy beams overlying lung. The values shown are the 
average of the differences in dose metrics between Plan 1 and Plan 4 and between Plan 3 and Plan 
5 (scattered beam value less scanned beam value). These plots illustrate the effect different R90 
values have on lung metrics. The general trend is that between scattered and scanned beams, as 
R90 increases, so do ΔV20Gy and ΔSCCPlin. The CW patient number is indicated inside the circles 
for Patient Set 1 (1,3,6) and squares for Patient Set 2 (2,4,7,8). 
Effects of using continuous versus discrete energy beams were best assessed by comparing 
Plan 1 with Plan 3 and Plan 4 with Plan 5 for Patient Set 1. Comparisons for Patient Set 2 were 
not particularly informative because the location of the edge of abutting the upper and lower fields 
abutment was not optimized. Plots of V20Gy and SCCPlin (discrete energy  beam value less 
continuous energy beam value) versus R90 suggested the general trend that these differences 
increased as R90 increased (see Figure 4.6). Although only data for three patients, all showed 
improvement with that for the highest energy beam (R90 = 6 cm) being the greatest, for Patient 1, 
reducing V20Gy and SCCPlin by as much as 3.1 % and 2.6%, respectively. Appreciate that this effect 
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could be negligible if the discrete energy selected is the optimal energy; however, in some cases 
both effects (large R90 and suboptimal energy) can be considerable.  
Combining these effects, scanned, continuous energy beams can provide treatment plans 
significantly superior to scattered, discrete energy beams. This is best illustrated by CW1, whose 
metrics for Plan 1 versus Plan 5 were reduced significantly, V20Gy from 17.2% to 10.7% and 
SCCPlin from 14.4% to 8.7%. 
 
Figure 4.6. Reduction in lung dose metrics (discrete energy beam value less continuous energy 
beam value) versus the average R90 of discrete and continuous energy beams overlying lung. The 
values shown are the average of the differences in dose metrics between Plan 1 and Plan 3 and 
between Plan 4 and Plan 5 (discrete beam value less continuous beam value) for patients in Patient 
Set 1. These plots illustrate the effect different R90 values have on lung metrics. The general trend 
is that between discrete and continuous beams as the R90 increases, so do ΔV30Gy and ΔSCCPlin. 
The CW patient number (1,3,6) is indicated inside the circles. 
4.3. Location of Abutting Edge 
Although the chest wall field can be treated with a single energy field using IM-BECT, it 
is often beneficial to treat a superior (upper) field using a higher electron energy and the inferior 
(lower) field using a lower electron energy, so as to reduce heart dose, as discussed above. This 
raises the questions of (1) where to put the abutting edge and (2) how to match the penumbras. 
The latter, described in this work, was achieved by using a common virtual source and feathering 
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the sharper, higher energy beam penumbra to closely match that of the broader, lower energy beam 
penumbra. 
Regarding the former, placing the edge too superior can result in having to increase the 
energy of the inferior field to the detriment of increasing heart dose. Placing the edge too inferior 
can result in greater dose than necessary to parts of the lung, as well as additional heart dose from 
the bulging of the high energy penumbra of the upper field into the heart. Such was the case in the 
present study by placing the edge 1 cm superior to the superior extent of the heart. This is illustrated 
by comparing the heart doses for Plan 2 and Plan 3 in Patient Set 2. For (CW2, CW4, CW7, and 
CW8), the V22.5Gy heart dose mostly increased from (3.1, 0.4, 11.6, and 3.4 Gy) to (8.4, 0.6, 12.8, 
and 3.3 Gy), and the Dmean heart dose changed from (4.6, 3.8, 9.7, and 4.2 Gy) to (8.1, 3.6, 9.7, and 
3.9 Gy); however, the NTCP decreased or remained the same from (0.9, 0.01, 0.5, and 0.1%) to 
(0.3, 0.01, 0.6, and 0.1%). The increased V22.5Gy was indicative of the encroachment of the higher 
energy dose, and the reduced NTCP was likely due to the differences in PTV volumes being 
treated.  
4.4. Comparison of IM-BECT with VMAT Plans 
The best IM-BECT plans can be compared with VMAT plans used to treat these patients 
at MBPCC, which have been previously reported.20 For Patient Set 1, Plan 5 (scanned, continuous 
energy beams) gives the best results and will be used for comparison. For Patient Set 2, Plan 4 
(scanned, discrete energy beams) will be used, as the optimal location of the edge of the abutting 
electron fields was not used in Plan 5. Plan comparisons for Patient Set 1 should be reasonable, as 
there was no supraclavicular field. However, comparison of plans in Patient Set 2 is somewhat 
presumptuous, as the current study did not include planning x-ray beams (possibly IMXT) for the 
supraclavicular field. However, assuming that supraclavicular fields contribute insignificantly to 
heart and lung dose, comparison of those metrics should be reasonable. 
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Selected metrics for the heart and lung are compared in Table 4.1 and Table 4.2, 
respectively. The results for Patient Sets 1 and 2 are similar; therefore, it is reasonable to report 
and discuss the results together, which are also computed (averages and standard deviations). 
Almost all data show that the standard deviations of VMAT plan metrics are small relative to those 
of the IM-BECT plans. This is possibly due to electron beam plans depending more on beam 
energy and t. Regardless, the increased spread means that some IM-BECT plans will be better or 
worse than the average, which means the degree of benefit of IM-BECT requires a plan comparison 
for the specific patient. 
Table 4.1. Comparison of heart dose and biologic metrics for IM-BECT and VMAT Plans from 
Doiron (2018).41 Plan 4 utilizes scanned, discrete energy beams for IM-BECT, and Plan 5 utilizes 
scanned, continuous energy beams for IM-BECT. 
 Modality-Plan V22.5Gy (%) Dmean (Gy) NTCP (%) 
Patient Set 1     
CW1 VMAT 9.7 9.0 0.7 
 IM-BECT Plan 5 2.3 4.3 0.05 
CW3 VMAT 5.5 7.0 0.3 
 IM-BECT Plan 5 1.5 3.7 0.03 
CW6 VMAT 11.5 10.9 1.6 
 IM-BECT Plan 5 8.2 5.8 0.40 
Mean (Std Dev) VMAT 8.9 (3.1) 9.0 (2.0) 0.87 (0.54) 
 IM-BECT Plan 5 4.0 (3.7) 4.6 (1.1) 0.16 (0.21) 
Patient Set 2     
CW2 VMAT 11.0 10.2 1.0 
 IM-BECT Plan 4 1.7 3.9 0.40 
CW4 VMAT 9.2 9.2 0.3 
 IM-BECT Plan 4 0.1 2.4 0.00 
CW7 VMAT 8.7 9.4 0.5 
 IM-BECT Plan 4 8.0 7.0 0.31 
CW8 VMAT 10.1 9.3 0.6 
 IM-BECT Plan 4 2.0 3.7 0.06 
Mean (Std Dev) VMAT 9.8 (1.0) 9.5 (0.5) 0.6 (0.3) 
 IM-BECT Plan 4 3.0 (3.5) 4.3 (2.0) 0.2 (0.2) 
Patient Sets 1 & 2     
Mean (Std Dev) VMAT 9.4 (2.0) 9.3 (1.2) 1.0 (0.7) 
 IM-BECT Plan 4/5 3.4 (3.3) 4.4 (1.5) 0.2 (0.2) 
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For the heart, on average, V22.5Gy dose is reduced from 9.8% for VMAT to 3.0% for IM-
BECT and Dmean is reduced from 9.3 Gy to 4.4 Gy. Although both are significant, NTCP is only 
reduced from 1.0% to 0.2%, as both are clinically low. So, although the dose reductions are 
significant, the NTCP models show minor clinical benefit. 
For the lungs, average V20Gy doses are similar, being 13.1% for VMAT and 13.0% for IM-
BECT; however, values are 14.1% and 9.2% for CW4, demonstrating patient variability. Average 
Dmean doses are reduced from 8.8 Gy to 7.1 Gy. Average NTCP is reduced from 2.8% to 0.2% and 
SCCPlin is reduced from 15.1% to 10.2%. These differences might further improve (increase) by 
optimizing the location of the abutting edge for IM-BECT Plan 5. 
Table 4.2. Comparison of lungs dose and biologic metrics for IM-BECT and VMAT Plans. Plan 
4 utilizes scanned, discrete energy beams for IM-BECT, and Plan 5 utilizes scanned, continuous 
energy beams for IM-BECT. 
 Modality-Plan V20Gy (%) Dmean (Gy) NTCP (%) SCCPlin 
Patient Set 1      
CW1 VMAT 13.4 8.7 2.7 14.9 
 IM-BECT Plan 5 10.7 5.2 0.01  8.7 
CW3 VMAT 13.1 8.8 2.8 15.1 
 IM-BECT Plan 5 12.5 5.6 0.01  9.4 
CW6 VMAT 14.3 9.9 3.4 16.8 
 IM-BECT Plan 5 16.8 7.6 0.02 12.8 
Mean (Std Dev) VMAT 13.6 (0.6) 9.1 (0.7) 3.0 (0.4) 15.6 (1.0) 
 IM-BECT Plan 5 13.3 (3.1) 6.1 (1.3) 0.01 (0.01) 10.3 (2.2) 
Patient Set 2      
CW2 VMAT 13.5  8.5 2.7 14.7 
 IM-BECT Plan 4 10.5  5.3 1.0  8.9 
CW4 VMAT 14.1  9.2 3.0 15.7 
 IM-BECT Plan 4  9.2  4.8  0.01  8.1 
CW7 VMAT 11.0  8.6 2.7 14.6 
 IM-BECT Plan 4 16.5 14.6  0.02 14.1 
CW8 VMAT 12.4  8.0 2.4 13.8 
 IM-BECT Plan 4 14.8  6.5  0.01  9.7 
Mean (Std Dev) VMAT 12.8 (1.4) 8.6 (0.5) 2.7 (0.3) 14.7 (0.8) 
 IM-BECT Plan 4 12.8 (3.5) 7.8 (4.6) 0.3 (0.5) 10.2 (2.7) 
Patient Sets 1 & 2      
Mean (Std Dev) VMAT 13.1 (1.1) 8.8 (0.6) 2.8 (0.3) 15.1 (0.9) 
 IM-BECT Plan 4/5 13.0 (3.1) 7.1 (3.4) 0.2 (0.4) 10.2 (2.3) 
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Chapter 5. Summary of Results, Conclusion, and Future Works 
5.1. Summary of Results 
5.1.1. IM-BECT Plans Using Different Electron Beam Machines 
IM-BECT treatment plans were generated for seven left-sided postmastectomy radiotherapy 
patients previously treated at MBPCC using VMAT. The patients were divided into two sets: 
Patient Set 1, which was comprised of three patients (CW1,CW3,CW6) and required a single 
electron field to treat the chest wall PTV, and Patient Set 2, which was comprised of four patients 
(CW2,CW4, CW7, CW8) and required two electron fields of differing energies to treat the chest 
wall PTV. For this study, only the chest wall PTV was studied, and the supraclavicular field, which 
requires photon beams to treat, was excluded. For patients in Patient Set 2, the inferior edge of the 
upper field was feathered to match the penumbra of the lower field. Thus, three beams were used 
to cover the chest wall PTV for these patients. 
Four IM-BECT treatment plans were made for each patient in Patient Set 1, and five IM-BECT 
plans were made for each patient in Patient Set 2. These plans spanned the spectrum from currently 
available electron radiotherapy technology, scattered, discrete energy beams, to hypothetical 
scanned, continuous energy beams. The treatment plans also included scattered, continuous energy 
beams and scanned, discrete energy beams. To determine the effects of using scattered vs. scanned 
beams, as well as the effects of using discrete vs. continuous energy spacing, the planar isodose 
plots, DVHs, and dose and biologic metrics were extracted from the dose distribution for each of 
32 plans.  
5.1.2. Impact of Machine Technology on Heart Dose 
Compared to other PMRT techniques, IM-BECT treatment plans typically have low heart 
dose,21 which is due to the use of conformal electron bolus and  dose distributions of electron 
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beams. For the seven patients studied, the V22.5Gy, V30Gy, and Dmean maximum values were 12.7%, 
6.4%, and 9.6 Gy for Plan 1, which uses currently deliverable scattered, discrete energy beams. 
These doses are low, having maximum NTCP of 0.9%.  
When comparing scattered and scanned beam metrics, V22.5Gy, V30Gy, and Dmean 
(scattered beam value less scanned beam value) versus R90 showed these metrics increased as R90 
increased, i.e. scanned beams showed the greatest effect (benefit) at the higher energies (Rp  5 
cm). For the seven patients studied, maximum V22.5Gy, V30Gy, and Dmean were reduced to 9.5%, 
4.2%, and 7.0 Gy for Plan 4, which could be deliverable by scanned, discrete energy beams. 
When comparing discrete and continuous energy beams, V22.5Gy, V30Gy, and Dmean 
(discrete energy beam value less continuous energy beam value) versus R90 suggested that these 
metrics increased as R90 increased. Although only data for three patients (Patient Set 1) was used, 
all showed improvement, that for the highest energy beam (R90 = 6 cm) being the greatest with 
V22.5Gy, V30Gy, and Dmean values being reduced by as much as 4.6 %, 2.2%, and 1.9 Gy, respectively. 
Of course, this effect could be negligible if the discrete energy selected was equal or near the 
optimal energy. 
In some patient cases, the effects of using both scanned and continuous energy beams were 
observed. This is clearer for patients in Patient Set 1 because there were no abutment issues. If we 
compare Plan 5 and Plan 1 metrics for CW1, there were reductions in V22.5Gy from 10.4% to 2.2%, 
V30Gy from 3.1% to 0.1%, Dmean from 8.3 Gy to 4.3 Gy, and NTCP from 0.4% to 0.1%. 
For all patients, the beam energy required for the lower field (based on maximum PTV 
thickness) and the thickness of tissue between the distal edge of the PTV and the heart (t) affected 
heart dose. Looking at Plan 1 for all patients shows that heart dose (1) decreased as the thickness 
of tissue (t) between the distal PTV edge and the heart increased and (2) increased as the R90 
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(hence energy) required for PTV coverage increased. Therefore, patient plans with the smaller t 
and greater R90 are those that possibly could benefit most from availability of scanned and/or 
continuous energy beams with regards to heart dose.  
5.1.3. Impact of Machine Technology on Lung Dose 
For all IM-BECT treatment plans, dose to the lung was low due to using electron beams with 
conformal bolus, as previously reported.41 For the seven patients studied, V20Gy values ranged from 
11.8% to 20.6% for Plan 1, the only plan deliverable using current scattered, discrete energy 
beams. These doses are acceptably low, having NTCP values ranging from 0.01% to1.4%. 
However, reducing SCCPlin values, which ranged from 10.9% to 18.6%, could be of concern. 
Effects of using scattered versus scanned beams were best assessed by comparing Plan 1 with 
Plan 4 and Plan 3 with Plan 5 for Patient Set 1, because they required only a single beam; however, 
comparisons for Patient Set 2 were also meaningful, even though Plans 3 and 5 did not have the 
optimal location of the abutment edge for the lower and upper fields. Plots of V20Gy and SCCPlin 
(scattered beam value less scanned beam value) versus R90 showed the general trend that lung 
sparing benefitted from scanned beams and that the benefit increased as R90 increased. For the 
seven patients studied, V20Gy values ranged from 9.2% to 17.8% and SCCPlin values ranged from 
8.1% to 13.7% for Plan 4 (scanned, discrete energy beams). Improving location of the abutting 
edge for the upper and lower electron fields should further increase the benefit for Patient Set 2. 
Effects of using continuous versus discrete energy beams were assessed by comparing Plan 1 
with Plan 3 and Plan 4 with Plan 5 for Patient Set 1. Plots of V20Gy and SCCPlin (discrete beam 
energy value less continuous beam energy value) versus R90 suggested the general trend that lung 
sparing benefitted from continuous beam energy and that the benefit increased as R90 increased. 
Although only data for three patients, all showed improvement. The greatest, Patient CW1 (R90 = 
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6 cm), showed V20Gy and SCCPlin reduced by 3.1 % and 2.6%, respectively. As for the heart, this 
effect could be negligible if the discrete energy selected was the optimal energy. 
In some cases, the effects of using both scanned and continuous energy beams are significant. 
This is clearest for patients in Patient Set 1 because there are no abutment issues. Comparing Plan 
5 metrics with Plan 1 metrics for CW1 shows that lung metrics are significantly reduced, V20Gy 
from 17.2% to 10.7% and SCCPlin from 14.4% to 8.7%. 
5.1.4. Impact of Location of Abutting Edge 
For patients in Patient Set 2, the location of the abutting edge had a significant impact on the 
dose distribution and the heart and lung metrics. Placing the edge too superior can result in having 
to increase the energy of the inferior field to the detriment of increasing heart dose. Placing the 
edge too inferior can result in greater dose than necessary to parts of the lung, as well as additional 
heart dose from the bulging of the high energy penumbra of the upper field into the heart. Such 
was the case in the present study by placing the edge 1 cm superior to the superior extent of the 
heart. This was illustrated by comparing the heart dose for Plan 2 and Plan 3 in Patient Set 2. For 
(CW2, CW4, CW7, and CW8), V22.5Gy heart dose generally increased or changed little, from (3.1, 
0.4, 11.6, and 3.4 Gy) to (8.4, 0.6, 12.8, and 3.3 Gy), and Dmean heart dose generally increased or 
changed little, from (4.6, 3.8, 9.7, and 4.2 Gy) to (8.1, 3.6, 9.7, and 3.9 Gy); however, NTCP 
decreased or changed little, from (0.9, 0.01, 0.5, and 0.1%) to (0.3, 0.01, 0.6, and 0.1%). For CW2 
the increased heart V22.5Gy was most indicative of the encroachment from the higher energy upper 
field. 
5.2. Response to Hypothesis 
Hypothesis: For seven post-mastectomy radiotherapy left-side chest wall patients 
previously treated with volumetric modulated arc therapy (VMAT), treatment plans using intensity 
modulated bolus electron conformal therapy (IM-BECT) with a scanned electron beam and/or the 
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capability of continuous energy spacing can be superior (increased sparing of heart and lung and 
reduced chance of secondary cancer) to plans made using IM-BECT with a passively scattered 
electron beam and discrete Elekta energy spacing. 
True, although a small sample of patients (seven), this study showed that IM-BECT treatment 
plans using scanned and/or continuous energy beams provided plans superior to plans using current 
scattered, discrete energy beams for some, but not all, patient plans. 
 
5.3. Potential Clinical Impact 
5.3.1. Impact of Scanned, Continuous Energy Beams 
Availability of scanned, continuous energy beams would provide treatment plans superior to 
those currently available, which use scattered, discrete energy beams. However, there are several 
caveats to consider and possibly further study.  
Previous studies have shown that IM-BECT offers increased dose sparing to the heart as 
opposed to other PMRT techniques.21 For some patients, that benefit can be further increased using 
scanned and/or continuous energy beams, as illustrated by this study. Better understanding of this 
benefit requires additional studies. Also, the NTCP for the scattered, discrete energy beam plan is 
quite low, perhaps minimizing the impact of improved plans. 
Shown in this study, lung dose can be reduced using scanned, continuous energy beams; 
however, the impact on NTCP is small, but perhaps of value for some patients. SCCPlin is 
significantly less using scanned, continuous energy beams, and it could likely be further improved 
by optimizing the abutting edge. 
The benefit of scanned, continuous energy beams depends on the patient geometry, specifically 
the depth of the PTV (hence R90) and the distance between the PTV distal surface and the proximal 
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surface of the heart (Δt). The benefits of using these proposed modalities varied between the 
different patients in this study. Further studies could better identify patient indications for using 
scanned, continuous energy electron beams. 
The current study was suboptimal due to its suboptimal methods of selecting the abutting edge 
of the upper and lower fields. Hence, benefit of scanned and/or continuous energy beams should 
improve with an optimized edge.  
It appears that the benefit of scanned beam technology might be more significant than 
continuous beam technology. This is in part due to the discrete energy beam possibly being the 
optimal energy. However, the scanned beam always produces a sharper dose falloff, improving 
the dose distribution. Also, the improvement in dose falloff (R90-10) is always more for scanned 
versus scattered beam than using a slightly lower beam energy available with continuous energy 
beams. 
5.3.2. Comparison of IM-BECT and VMAT Treatment Plans 
The best possible IM-BECT plans, Plan 5 for Patient Set 1 and Plan 4 for Patient Set 2, 
were compared with patient VMAT plans from our clinic.20 Because the IM-BECT plans excluded 
the supraclavicular PTV, only lung and heart dose were compared. 
For heart dose, the average V22.5Gy was reduced from 9.8% for VMAT to 3.0% for IM-
BECT, and average Dmean was reduced from 9.3 Gy to 4.4 Gy. Although such reductions were 
significant, NTCP models showed only minor average reduction from 1.0% to 0.2%, both 
clinically low. 
For lung dose, the average V20Gy doses were similar, 13.1% for VMAT and 13.0% for IM-
BECT; however, values were 14.1% and 9.2%, respectively for CW4, demonstrating patient 
variability for benefits of IM-BECT. Average Da was reduced from 8.8 Gy to 7.1 Gy; however, 
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average NTCP was reduced from 2.8% to 0.2%, and average SCCPlin was reduced from 15.1% to 
10.2%. SCCPlin was reduced from 15.7% to 8.1% for CW4, demonstrating the potential benefit 
for a single patient. 
These results show that for some patients, IM-BECT can provide plans that are 
significantly superior to VMAT. 
5.4. Recommendations for Future Investigation 
5.4.1. Revised Simple Planning Method 
In future studies, it is recommended that only four plans be generated for each patient in 
Patient Set 2, as was the done in Patient Set 1. The four plans should use (1) scattered, discrete 
energy beams, (2) scattered, continuous energy beams, (3) scanned, discrete energy beams, and 
(4) scanned, continuous energy beams. Each plan should use the following steps: 
1. Location of Abutting Edge: Select the lowest continuous energy (R90) possible for 
a field covering only the heart PTV. Then, move the superior edge of the lower 
field superiorly as much as possible, while treating the chest wall with the 90% 
dose surface. That field edge specifies the abutting edge of the lower and upper 
fields for Plans 1 – 4. 
2. Lower and Upper Field Beam Energies: Select the lowest available energies 
available (discrete or continuous depending) for the lower and upper fields for 
which the 90% dose surface contains the PTV. 
3. Edge Feathering: Use the same procedure for feathering of the upper field edge as 
specified in the present methods. 
Alternatively, the lowest energy (continuous or discrete) possible for a field covering only 
the heart PTV can be used. Then, the superior edge of the lower field can be moved superiorly as 
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much as possible while treating the chest wall with the 90% dose surface. That field edge is used 
only for that plan.  
5.4.2. Revised Complex Planning Method 
This method optimizes the location of the abutting edge. It is recommended that a fast 
method be developed for finding the optimal location of the abutting edge between the upper, 
greater energy field and the lower, lesser energy field. This is needed for those patients in Patient 
Set 2, which required upper and lower fields of differing beam energy. 
In the present study, in Plans 3 and 5, the edge was 1.0 cm superior to the superior aspect 
of the heart. This allowed selection of the lowest available energy for the field overlying the heart; 
however, it did not necessarily give the lowest heart dose, due to dose from the bulging edge of 
the higher energy upper field reaching the heart. Also, because the energy had to be sufficiently 
high to cover the superior aspect of the chest wall, where PTV depth can be deeper, it resulted in 
a higher dose than needed over portions of the lung. Although bolus electron conformal therapy 
places R90 at the distal PTV, a higher energy than necessary results in a greater R90-10, giving 
greater than necessary dose to lung. As the field edge is moved superiorly, the lung receives less 
dose, as a greater portion of the lung is irradiated with the lower energy lower field. However, the 
heart dose can increase if a slightly greater energy is required. Therefore, any optimization criteria 
need to quantify the benefit of these competing effects of decreased lung dose at the expense of 
increased heart dose. 
5.4.3. Increasing Number of Patients for the Study 
It is recommended that the number of patients in the study be increased approximately an 
order of magnitude. Results showed that the amount of heart dose depended on the distance 
between the distal PTV surface and the heart R90 of the energy required for the lower field.  
117 
In addition, the benefit of continuous versus discrete energy beams, for both lung and heart 
dose, depends on how close the ideal continuous energy is to the next greatest discrete energy 
required. Also, the benefit of scanned versu41s scattered beams is greatest for higher energy beam 
( 15 MeV). Therefore, for the right conditions, currently available scattered, discrete energy 
beams might be very close to optimal. Also, for the right conditions, scanned and/or continuous 
energy beams might significantly improve treatment than using currently available scattered, 
discrete energy beams. Hence, a larger number of patients is required to determine the fraction that 
might benefit and the amount they might benefit from either scattered, continuous energy; scanned, 
discrete energy; or scanned, continuous energy beams. 
5.4.4. Including the Supraclavicular Field in the Study 
New IM-BECT patient plans should also include comparison with VMAT treatment plans. 
To make that comparison complete, the supraclavicular PTV should be included with the electron 
plan, treated either with VMAT or opposed IMXT as demonstrated by Doiron (2018). This should 
demonstrate the benefit of IM-BECT over VMAT for currently available scattered, discrete energy 
beams, as well as potential future beams using scattered, continuous energy beams; scanned, 
discrete energy beams; or scanned, continuous energy beams. 
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Appendix A. Description of p.d Bolus Design Operators 
 
(table cont’d) 
Operators used to design the bolus for ECT using p.d are based on a subset of the operators of 
Low et al. (1992) with some small changes. For more detail, refer to the p.d user manual. 
Construction and Extension Operators 
Creation Operator, Cp (𝑹𝒕,𝑰) 
Rt is a user specified therapeutic range (typically R90). 
∆𝑰 is a user specified target inner margin, which is a distance, in the plane of the 
isocenter, between the edge of the target volume and the solid angle within which the 
initial bolus is designed. 
This operator creates an initial bolus surface. With respect to the source, the proximal 
patient skin surface defines the distal bolus surface. Cp only defines proximal bolus surface 
for ray-lines intersecting the target volume less target inner margin (TVLM) by bolus 
thickness 𝒃𝒊,𝒋 along each (i,j) ray-line, where 𝒃𝒊,𝒋 = (𝑹𝒕 − 𝒅𝒊,𝒋) 
where: 
𝒅𝒊,𝒋 is the distance from the proximal patient surface to the distal target surface along the 
(𝒊, 𝒋) ray-line; 
Note: If 𝒃𝒊,𝒋 < 𝟎. 𝟐 𝒄𝒎, 𝒃𝒊,𝒋 = 𝟎. 𝟐 𝒄𝒎.  
The bolus surface is extended laterally using the height extension operator below. 
Height Extension Operator, Hh (𝑰,𝑶) 
∆𝑶 is a user specified block outer border margin, which is the distance, in the isocenter 
plane, between the inner edge of the custom electron applicator (block) and the 
unmilled region of the wax bolus (i.e. the block outer border). 
This operator extends bolus height on (i,j) ray-lines within the TVLM to the block outer 
border. The extended bolus heights 𝑯𝒊′,𝒋′ are defined separately for three zones (Low et al. 
1992). In this work bolus heights in zone 1 were defined as the shorter of 𝒉𝒊,𝒋 or the 
harmonic mean of (𝒉𝒊,𝒋)𝒙 and (𝒉𝒊,𝒋)𝒚. Zones 2 and 3 are defined as per Low et al. 
where: 
 𝒉𝒊,𝒋 is the nearest neighbor of 𝑯𝒊′,𝒋′ within the TVLM. 
(𝒉𝒊,𝒋)𝒙 is the nearest neighbor of 𝑯𝒊′,𝒋′, where 𝒋 = 𝒋′. 
(𝒉𝒊,𝒋)𝒚 is the nearest neighbor of 𝑯𝒊′,𝒋′, where 𝒊 = 𝒊′. 
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Table A.1 Description of p.d Bolus Design Operators, cont. 
Modification Operators 
Isodose Shift Operator, I (%D,𝑰) 
%D is a user definition of a distal percent dose surface (𝒅𝒊,𝒋)%𝑫
 specified as percent given 
dose. (Typically, %D = 90%) 
Isodose Shift tries to match (𝒅𝒊,𝒋)%𝑫
 to a distal target surface (𝒅𝒊,𝒋 )𝒕𝒂𝒓𝒈𝒆𝒕
 by modifying 
bolus thickness (𝒃𝒊,𝒋)𝒐𝒍𝒅
 as (𝒃𝒊,𝒋)𝒏𝒆𝒘
= (𝒃𝒊,𝒋)𝒐𝒍𝒅
+ (𝒅𝒊,𝒋)%𝑫
 − (𝒅𝒊,𝒋 )𝒕𝒂𝒓𝒈𝒆𝒕
. 
Smoothing Operator, Gh (𝝁, 𝜼, 𝒑𝒔) 
𝝁 is a user specified exponential smoothing weight coefficient. 
𝜼 is a user specified smoothing region size factor. 
a2 is a predefined to be 15mm. 
(𝒉𝒊,𝒋)𝒔𝒎𝒐𝒐𝒕𝒉
(𝝁, 𝜼, 𝒑𝒔) =  
∑ [𝒉𝒊′,𝒋′𝒆
−𝝁𝒓𝟐 (𝟐𝒂𝟐)⁄ ]𝜼𝒂
∑ [𝒆−𝝁𝒓
𝟐 (𝟐𝒂𝟐)⁄ ]𝜼𝒂
 
where: 
 (𝒉𝒊,𝒋)𝒔𝒎𝒐𝒐𝒕𝒉
is the smoothed bolus height on each (𝒊, 𝒋) ray-line. 
a is bolus point spacing ps projected on each (𝒊, 𝒋) ray-line to the distal target surface. 
𝒉𝒊′,𝒋′ is unsmooth bolus height along (𝒊
′, 𝒋′) ray-lines within the region 𝜼𝒂. 
r is the distance from an (𝒊, 𝒋) ray-line to an (𝒊′, 𝒋′) ray-line, where r ≤ 𝜼𝒂. 
Specified Shift Operator, S (,𝑶) 
 is a specified shift of the milled bolus surface. 
This operator shifts the entire proximal bolus surface inside the block outer border toward 
the beam source by , effectively changing the bolus thickness along each (i,j) ray-line to 
𝒃𝒊,𝒋 = 𝒃𝒊,𝒋 + . A negative value of  shifts the entire proximal bolus surface inside the 
block outer border away from the beam source, shifting isodose lines (IDL) deeper into the 
patient. 
Truncation Operator, T (𝑶) 
This operator only modifies the proximal bolus surface outside the block outer border 
defined by 𝑶 by truncating bolus height 𝒉𝒊,𝒋 on each (i,j) ray to (𝒉𝒊,𝒋)𝒎𝒂𝒙. 
where: 
(𝒉𝒊,𝒋)𝒎𝒂𝒙 is the maximum bolus surface height within the block outer border. 
Modulate Intensity Operator, M (𝑰, 𝒘𝒎𝒂𝒙) 
This operator modifies weights wi,j of each PBRA pencil beam intersecting the TVLM, i.e. 
within 𝑰, as (𝒘𝒊,𝒋)𝒏𝒆𝒘
= (𝒘𝒊,𝒋)𝒐𝒍𝒅
∙ 𝒎𝒊𝒏[𝒘𝒎𝒂𝒙, 𝟏𝟎𝟎% 𝒅𝒎𝒂𝒙(𝒊,𝒋)⁄  ]. Presently, the 1
st 
application of M in p.d uses (𝒘𝒊,𝒋)𝒐𝒍𝒅
= (𝒘𝒊,𝒋)𝒊𝒏𝒊𝒕𝒊𝒂𝒍
= 𝟏. 𝟎 . 
where: 
𝒅𝐦𝐚𝐱(𝒊,𝒋) is the maximum dose along each (i,j) ray-line. 
𝒘𝒎𝒂𝒙 is the un-normalized maximum pencil beam weight (1.1 in this work). 
Outside the TVLM, IM weights are extended according to Low et al. 
The pencil beam weights are converted to a island block distribution for calculation as 
described by Hilliard30 
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Appendix B. Treatment Planning Results 
B.1. Patient Set 1 (CW1, CW3, CW6) 
  
Figure B.1. Sagittal and axial images of CW1, Plan 1. CW1 (Patient Set 1) was planned using 
scattered electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique 
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane 
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Bolus is 
shaded blue, and PTV is outlined in white. Key shows dose values. 
(figure cont’d.) 
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Figure B.2. Sagittal and axial images of CW1, Plan 2. CW1 (Patient Set 1) was planned using 
scattered electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal, 
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in 
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique 
plane. Bolus is shaded blue, and PTV is outlined in white. Key shows dose values. 
(figure cont’d.) 
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Figure B.3. Sagittal and axial images of CW1, Plan 4. CW1 (Patient Set 1) was planned using 
scanned electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique 
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane 
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Bolus is 
shaded blue, and PTV is outlined in white. Key shows dose values. 
(figure cont’d.) 
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Figure B.4. Sagittal and axial images of CW1, Plan 5. CW1 (Patient Set 1) was planned using 
scanned electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal, 
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in 
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique 
plane. Bolus is shaded blue, and PTV is outlined in white. Key shows dose values. 
(figure cont’d.) 
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Figure B.5. Sagittal and axial images of CW3, Plan 1. CW3 (Patient Set 1) was planned using 
scattered electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique 
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane 
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Bolus is 
shaded blue, and PTV is outlined in white. Key shows dose values. 
(figure cont’d.) 
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Figure B.6. Sagittal and axial images of CW3, Plan 3. CW3 (Patient Set 1) was planned using 
scattered electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal, 
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in 
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique 
plane. Bolus is shaded blue, and PTV is outlined in white. Key shows dose values. 
(figure cont’d.) 
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Figure B.7. Sagittal and axial images of CW3, Plan 4. CW3 (Patient Set 1) was planned using 
scanned electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique 
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane 
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Bolus is 
shaded blue, and PTV is outlined in white. Key shows dose values. 
(figure cont’d.) 
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Figure B.8. Sagittal and axial images of CW3, Plan 5. CW3 (Patient Set 1) was planned using 
scanned electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal, 
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in 
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique 
plane. Bolus is shaded blue, and PTV is outlined in white. Key shows dose values. 
(figure cont’d.) 
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Figure B.9. Sagittal and axial images of CW6, Plan 1. CW6 (Patient Set 1) was planned using 
scattered electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique 
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane 
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Bolus is 
shaded blue, and PTV is outlined in white. Key shows dose values. 
(figure cont’d.) 
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Figure B.10. Sagittal and axial images of CW6, Plan 3. CW6 (Patient Set 1) was planned using 
scattered electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal, 
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in 
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique 
plane. Bolus is shaded blue, and PTV is outlined in white. Key shows dose values. 
(figure cont’d.) 
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Figure B.11. Sagittal and axial images of CW6, Plan 4. CW6 (Patient Set 1) was planned using 
scanned electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique 
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane 
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Bolus is 
shaded blue, and PTV is outlined in white. Key shows dose values. 
(figure cont’d.) 
141 
142 
 
Figure B.12. Sagittal and axial images of CW6, Plan 5. CW6 (Patient Set 1) was planned using 
scanned electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal, 
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in 
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique 
plane. Bolus is shaded blue, and PTV is outlined in white. Key shows dose values. 
(figure cont’d.) 
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B.2. Patient Set 2 (CW2, CW4, CW7, CW8) 
 
Figure B.13. Sagittal and axial images of CW2, Plan 1. CW2 (Patient Set 2) was planned using 
scattered electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique 
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane 
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Upper 
bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in white. Key 
shows dose values. 
(figure cont’d.) 
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Figure B.14. Sagittal and axial images of CW2, Plan 2. CW2 (Patient Set 2) was planned using 
scattered electron beams and discrete (lower field)/continuous (upper field) energy spacing. (a) 
Dose plan in the sagittal-coronal, oblique plane demarcated by the red line in figure (b)’s transverse 
plane; (b) Dose plan in transverse plane passing through central heart region, demarcated by red 
line in figure (a)’s oblique plane. Upper bolus is shaded dark blue, lower bolus is shaded light blue, 
and PTV is outlined in white. Key shows dose values. 
(figure cont’d.) 
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Figure B.15. Sagittal and axial images of CW2, Plan 3. CW2 (Patient Set 2) was planned using 
scattered electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal, 
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in 
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique 
plane. Upper bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in 
white. Key shows dose values. 
(figure cont’d.) 
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Figure B.16. Sagittal and axial images of CW2, Plan 4. CW2 (Patient Set 2) was planned using 
scanned electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique 
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane 
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Upper 
bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in white. Key 
shows dose values. 
(figure cont’d.) 
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Figure B.17. Sagittal and axial images of CW2, Plan 5. CW2 (Patient Set 2) was planned using 
scanned electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal, 
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in 
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique 
plane. Upper bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in 
white. Key shows dose values. 
(figure cont’d.) 
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Figure B.18. Sagittal and axial images of CW4, Plan 1 and Plan 2. CW4 (Patient Set 2) was 
planned using scattered electron beams and discrete energy spacing for Plan 1 and discrete (lower 
field)/continuous (upper field) energy spacing for Plan 2. In this case, the optimal energy for the 
upper field was discrete so the Plans 1 and 2 are identical. (a) Dose plan in the sagittal-coronal, 
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in 
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique 
plane. Upper bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in 
white. Key shows dose values. 
(figure cont’d.) 
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Figure B.19. Sagittal and axial images of CW4, Plan 3. CW4 (Patient Set 2) was planned using 
scattered electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal, 
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in 
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique 
plane. Upper bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in 
white. Key shows dose values. 
(figure cont’d.) 
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Figure B.20. Sagittal and axial images of CW4, Plan 4. CW4 (Patient Set 2) was planned using 
scanned electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique 
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane 
passing through central heart region, demarcated by red line in figure (a)’s oblique plane Upper 
bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in white. Key 
shows dose values. 
(figure cont’d.) 
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Figure B.21. Sagittal and axial images of CW4, Plan 5. CW4 (Patient Set 2) was planned using 
scanned electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal, 
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in 
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique 
plane. Upper bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in 
white. Key shows dose values. 
(figure cont’d.) 
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Figure B.22. Sagittal and axial images of CW7, Plan 1 and Plan 2. CW7 (Patient Set 2) was 
planned using scattered electron beams and discrete energy spacing for Plan 1 and discrete (lower 
field)/continuous (upper field) energy spacing for Plan 2. In this case, the optimal energy for the 
upper field was discrete so the Plans 1 and 2 are identical. (a) Dose plan in the sagittal-coronal, 
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in 
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique 
plane. Upper bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in 
white. Key shows dose values. 
(figure cont’d.) 
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Figure B.23. Sagittal and axial images of CW7, Plan 3. CW7 (Patient Set 2) was planned using 
scattered electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal, 
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in 
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique 
plane. Upper bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in 
white. Key shows dose values. 
(figure cont’d.) 
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Figure B.24. Sagittal and axial images of CW7, Plan 4. CW7 (Patient Set 2) was planned using 
scanned electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique 
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane 
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Upper 
bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in white. Key 
shows dose values. 
(figure cont’d.) 
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Figure B.25. Sagittal and axial images of CW7, Plan 5. CW7 (Patient Set 2) was planned using 
scanned electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal, 
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in 
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique 
plane. Upper bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in 
white. Key shows dose values. 
(figure cont’d.) 
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Figure B.26. Sagittal and axial images of CW8, Plan 1. CW8 (Patient Set 2) was planned using 
scattered electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique 
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane 
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Upper 
bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in white. Key 
shows dose values. 
(figure cont’d.) 
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Figure B.27. Sagittal and axial images of CW8, Plan 2. CW8 (Patient Set 2) was planned using 
scattered electron beams and discrete (lower field)/continuous (upper field) energy spacing. (a) 
Dose plan in the sagittal-coronal, oblique plane demarcated by the red line in figure (b)’s transverse 
plane; (b) Dose plan in transverse plane passing through central heart region, demarcated by red 
line in figure (a)’s oblique plane. Upper bolus is shaded dark blue, lower bolus is shaded light blue, 
and PTV is outlined in white. Key shows dose values. 
(figure cont’d.) 
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Figure B.28. Sagittal and axial images of CW8, Plan 3. CW8 (Patient Set 2) was planned using 
scattered electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal, 
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in 
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique 
plane. Upper bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in 
white. Key shows dose values. 
(figure cont’d.) 
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Figure B.29. Sagittal and axial images of CW8, Plan 4. CW8 (Patient Set 2) was planned using 
scanned electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique 
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane 
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Upper 
bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in white. Key 
shows dose values. 
(figure cont’d.) 
177 
178 
 
Figure B.30. Sagittal and axial images of CW8, Plan 5. CW8 (Patient Set 2) was planned using 
scanned electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal, 
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in 
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique 
plane. Upper bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in 
white. Key shows dose values. 
(figure cont’d.) 
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